<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pentasaccharides for the treatment of deep vein thrombosis - Brandao, GMS - 2017 | Cochrane Library</title> <meta content="Pentasaccharides for the treatment of deep vein thrombosis - Brandao, GMS - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011782.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pentasaccharides for the treatment of deep vein thrombosis - Brandao, GMS - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011782.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011782.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pentasaccharides for the treatment of deep vein thrombosis" name="citation_title"/> <meta content="Gustavo MS Brandao" name="citation_author"/> <meta content="Faculdade de Medicina de Botucatu" name="citation_author_institution"/> <meta content="gubrandao@terra.com.br" name="citation_author_email"/> <meta content="Daniela R Junqueira" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="Hamilton A Rollo" name="citation_author"/> <meta content="Faculdade de Medicina de Botucatu" name="citation_author_institution"/> <meta content="Marcone L Sobreira" name="citation_author"/> <meta content="Faculdade de Medicina de Botucatu" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD011782.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/12/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011782.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011782.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011782.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [administration &amp; dosage, adverse effects, *therapeutic use]; Biotin [administration &amp; dosage, adverse effects, *analogs &amp; derivatives, therapeutic use]; Fondaparinux; Hemorrhage [chemically induced]; Heparin, Low‐Molecular‐Weight [therapeutic use]; Oligosaccharides [administration &amp; dosage, adverse effects, *therapeutic use]; Polysaccharides [administration &amp; dosage, adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Recurrence; Time Factors; Venous Thrombosis [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011782.pub2&amp;doi=10.1002/14651858.CD011782.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ytRBD0EW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011782\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011782\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011782.pub2",title:"Pentasaccharides for the treatment of deep vein thrombosis",firstPublishedDate:"Dec 2, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011782.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011782.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011782.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011782.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011782.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011782.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011782.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011782.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011782.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011782.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2123 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011782.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-sec-0147"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-sec-0124"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/appendices#CD011782-sec-0152"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/table_n/CD011782StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/table_n/CD011782StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pentasaccharides for the treatment of deep vein thrombosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information#CD011782-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Gustavo MS Brandao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information#CD011782-cr-0003">Daniela R Junqueira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information#CD011782-cr-0004">Hamilton A Rollo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information#CD011782-cr-0005">Marcone L Sobreira</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information/en#CD011782-sec-0156">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 December 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011782.pub2">https://doi.org/10.1002/14651858.CD011782.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011782-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011782-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011782-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011782-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011782-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011782-abs-0001" lang="en"> <section id="CD011782-sec-0001"> <h3 class="title" id="CD011782-sec-0001">Background</h3> <p>Standard treatment of deep vein thrombosis (DVT) is based on antithrombotic therapy, initially with parenteral administration of unfractionated heparin or low molecular weight heparins (LMWH) for five to seven days, then subsequent long‐term therapy with oral vitamin K antagonists (e.g. warfarin). Pentasaccharides are novel anticoagulants that may be favourable over standard therapy due to their predictable effect, no need for frequent monitoring or re‐dosing, and few known drug interactions. Heparin‐induced thrombocytopenia, a harmful effect of heparins, appears to be rare during treatment with pentasaccharides. </p> </section> <section id="CD011782-sec-0002"> <h3 class="title" id="CD011782-sec-0002">Objectives</h3> <p>To assess the efficacy and harms of pentasaccharides for the treatment of deep vein thrombosis. </p> </section> <section id="CD011782-sec-0003"> <h3 class="title" id="CD011782-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (22 March 2017) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 2) (searched 22 March 2017). We searched clinical trials databases for details of ongoing or unpublished studies and the reference lists of relevant articles for additional citations. </p> </section> <section id="CD011782-sec-0004"> <h3 class="title" id="CD011782-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials in which people 18 years of age or older with a DVT confirmed by standard imaging techniques were allocated to receive a pentasaccharide (fondaparinux, idraparinux, or idrabiotaparinux) for the treatment of DVT in comparison with standard therapy or other treatments. </p> </section> <section id="CD011782-sec-0005"> <h3 class="title" id="CD011782-sec-0005">Data collection and analysis</h3> <p>We extracted data characterising the included trials according to the methods, participants, interventions, and outcomes. We assessed risk of bias using Cochrane's 'Risk of bias' tool and employed the GRADE methodology to evaluate the quality of the evidence. </p> <p>The main primary outcome for efficacy was recurrent venous thromboembolism (VTE), and the main primary outcome for harm was major and clinically relevant bleeding. Since our outcomes were dichotomous, we calculated the risk ratio (RR) with a 95% confidence interval (CI). We combined the effects of different comparisons through a meta‐analysis using a fixed‐effect model. </p> </section> <section id="CD011782-sec-0006"> <h3 class="title" id="CD011782-sec-0006">Main results</h3> <p>We included five randomised controlled trials of 6981 participants comparing pentasaccharides with standard therapy or other pentasaccharides. The quality of the evidence varied depending on the outcome and was judged as of moderate to very low quality. We downgraded the quality of the evidence due to risk of bias or imprecision, or both. </p> <p>Two studies evaluated fondaparinux, at doses of 5.0 mg, 7.5 mg, and 10.0 mg, plus vitamin K antagonist in comparison with standard therapy. A meta‐analysis of these two studies showed no clear difference in the risk of recurrent VTE (RR 0.80, 95% CI 0.43 to 1.47; 2658 participants); moderate‐quality evidence. The frequencies of major bleeding were similar between interventions in the initial period of treatment (approximately five days) (RR 1.15, 95% CI 0.39 to 3.44; 2645 participants) and at three months' follow‐up (RR 1.05, 95% CI 0.64 to 1.71; 2645 participants). We judged the quality of the evidence as moderate. </p> <p>One study (757 participants) compared idrabiotaparinux (3.0 mg) with idraparinux (2.5 mg) and demonstrated no clear difference in the risk of recurrent VTE at six months' follow‐up (RR 0.72, 95% CI 0.31 to 1.69); low‐quality evidence. Major bleeding during the initial treatment period was not reported. Major bleeding at six‐month follow‐up was less frequent in participants receiving idrabiotaparinux versus participants treated with idraparinux (RR 0.21, 95% CI 0.06 to 0.71); low‐quality evidence. </p> <p>The effect of an initial treatment with LMWH followed by three months of idraparinux (10 mg) showed no clear difference from standard therapy for risk of recurrent VTE (RR 1.51, 95% CI 0.26 to 8.90; 263 participants); very low‐quality evidence; one study. Major bleeding during the initial treatment period was not reported. The frequency of major and other clinically relevant bleeding at three months' follow‐up ranged from 2% to 15% in participants receiving LMWH and increasing doses of idraparinux of 2.5 mg, 5 mg, 7.5 mg, or 10 mg. When dosage groups were combined, there was no clear difference in major plus other clinically relevant bleeding or in major bleeding alone between the idraparinux treatment group and the standard therapy group (RR 1.30, 95% CI 0.70 to 2.40; 659 participants; RR 3.76, 95% CI 0.50 to 28.19; 659 participants, respectively); very low‐quality evidence. </p> <p>One study (2904 participants) compared idraparinux (2.5 mg) to standard therapy. There was no clear difference in the risk of recurrent VTE at three months' follow‐up (RR 0.98, 95% CI 0.64 to 1.48); low‐quality evidence. Major bleeding during the initial treatment period was not reported. Major bleeding at three months of follow‐up appeared to be similar in the idraparinux group and the standard therapy group (RR 0.71, 95% CI 0.34 to 1.47); very low‐quality evidence. </p> </section> <section id="CD011782-sec-0007"> <h3 class="title" id="CD011782-sec-0007">Authors' conclusions</h3> <p>We found moderate‐quality evidence that the effects of fondaparinux at doses of 5.0 mg, 7.5 mg, and 10.0 mg plus vitamin K antagonist are similar in terms of recurrent VTE and risk of major bleeding compared with standard treatment for DVT. </p> <p>Low‐quality evidence suggests equal efficacy of idraparinux at 2.5 mg and the equimolar dose of 3.0 mg of idrabiotaparinux with regard to recurrent VTE, but a higher frequency of major bleeding was observed in participants treated with idraparinux. </p> <p>We judged evidence on the effectiveness of idraparinux compared with standard therapy, with or without initial treatment with LMWH, and on associated bleeding risk to be low to very low quality, therefore we have very limited confidence in the estimated effects. </p> <p>The observed similar effectiveness in terms of recurrent DVT and harmful effects in terms of bleeding risk with fondaparinux plus vitamin K antagonist compared to standard treatment for DVT suggest that it may be an alternative to conventional anticoagulants for the treatment of DVT in certain circumstances. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011782-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011782-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011782-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011782-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011782-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011782-abs-0005">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011782-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011782-abs-0003" lang="en"> <h3>Pentasaccharides for the treatment of deep vein thrombosis</h3> <p><b>Review question</b> </p> <p>Are fondaparinux, idraparinux, and idrabiotaparinux, new anticoagulants (blood‐thinning medications) of the class of the pentasaccharides, a safe and effective alternative to conventional anticoagulants used to treat deep vein thrombosis? </p> <p><b>Background</b> </p> <p>Deep vein thrombosis is a severe and life‐threatening disease caused by the formation of a blood clot in the deep veins, usually in the legs. The conventional treatment consists of injections of the anticoagulant heparins for five to seven days, followed by long‐term therapy with oral anticoagulants (vitamin K antagonists, e.g. warfarin). However, the high risk of bleeding and need for frequent laboratory control are important limitations to conventional therapy. </p> <p>The pentasaccharides fondaparinux, idraparinux, and idrabiotaparinux have a more predictable effect and a more convenient dosing regimen in comparison with the conventional treatment. Pentasaccharides also do not require laboratory control and have few known interactions with other medicines and foods. They may be more cost‐effective in many settings, and a harmful effect known as heparin‐induced thrombocytopenia (heparin injections causing an increase in the risk of clotting (thromboembolic) complications) appears to be rare during treatment with pentasaccharides. Possible limitations of pentasaccharides are that they may be harmful in people with severe renal insufficiency and the need for intravenous or subcutaneous injections to administer these medications. </p> <p><b>Study characteristics and key results</b> </p> <p>After searching the literature for relevant studies, current until 22 March 2017, we included five studies with a total of 6981 participants. The included studies compared fondaparinux, idraparinux, and idrabiotaparinux versus conventional therapy or each another. Our main outcome to judge the effectiveness of the treatments was the occurrence of a recurrent venous thromboembolism (an episode of deep vein thrombosis or pulmonary embolism), and our main outcome to evaluate the harmful effects of the treatments was major and clinically relevant bleeding. </p> <p>Our review showed that the pentasaccharide fondaparinux (at doses of 5.0 mg, 7.5 mg, and 10.0 mg) plus vitamin K antagonist may show similar effectiveness and harmful effects compared to the conventional treatment for deep vein thrombosis. Idraparinux at the dose of 2.5 mg and idrabiotaparinux at the dose of 3.0 mg resulted in relatively high numbers of bleeding<b>.</b> </p> <p><b>Quality of the evidence</b> </p> <p>We judged our main results on the effectiveness and harms of fondaparinux plus vitamin K antagonist compared with conventional treatment as of moderate quality. This means that we are confident that these results may be correct, though additional studies could possibly change the estimates. Additonal evidence was largely imprecise and deemed of low to very low quality depending on the outcome. We downgraded the quality of the evidence for risk of bias or imprecision, or both. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011782-sec-0147" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011782-sec-0147">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011782-sec-0201">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011782-sec-0147"></div> <h3 class="title" id="CD011782-sec-0148">Implications for practice</h3> <section id="CD011782-sec-0148"> <p>We found moderate‐quality evidence that fondaparinux at doses of 5.0 mg, 7.5 mg, and 10.0 mg, with or without weight adjustment, plus vitamin K antagonist, has similar effectiveness in terms of recurrent venous thromboembolism and a similar risk of major bleeding compared with standard treatment for deep vein thrombosis (DVT). The frequency of all harmful outcomes appeared to be comparable between fondaparinux plus vitamin K antagonist and standard treatment, though the quality of the evidence was very low. Evidence from subgroup analysis suggests there could be a reduced efficacy of fondaparinux in obese patients with body weight greater than 100 kg and in people with cancer, and also a poor effectiveness/risk balance in people receiving outpatient care, needs to be interpreted with caution. </p> <p>Treatment with fondaparinux is more convenient since it requires only one subcutaneous administration per day, while low molecular weight heparins (LMWH) require two subcutaneous injections per day. This convenient dosage facilitates outpatient treatment and early discharge from hospital. Fondaparinux also has a more predictable anticoagulant response, therefore with no need for laboratory monitoring of the anticoagulant effect, and its profile of drug interactions is more favourable since it is not metabolised in the liver. Addionally, fondaparinux appears to be more cost‐effective in different settings (<a href="./references#CD011782-bbs2-0022" title="CapriS , AgenoW , ImbertiD , PalaretiG , PiovellaF , ScannapiecoG , et al. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost‐effectiveness analysis. Internal and Emergency Medicine 5;1:33‐40. ">Capri 2010</a>; <a href="./references#CD011782-bbs2-0077" title="SullivanSD , KwongL , NutescuE . Cost‐effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. Value Health2006;9(2):68‐76. ">Sullivan 2006</a>). Considering only the price of the medicines, in low‐ and middle‐income countries such as Brazil treatment with fondaparinux for DVT may be almost 75% less expensive than treatment with the LMWH enoxaparin (<a href="./references#CD011782-bbs2-0012" title="Brasil. Agência Nacional de Vigilância Sanitária(Anvisa) . Price of medicines commercialised in the country [Lista de preço de medicamentos comercializados no país]. novoportal.anvisa.gov.br/listas‐de‐precos (accessed prior to 5 November 2017). ">Anvisa 2016</a>). </p> <p>In this context, the drawback of fondaparinux would be the lack of an antidote capable to reverse its anticoagulant effect. Neverthless, in 2016, the US Food and Drug Administration (FDA) accepted the Biologics License Application for a reversal agent to direct and indirect factor Xa inhibitors. Andexanet alfa is a recombinant human factor Xa protein that is catalytically inactive but that retains the ability to bind factor inhibitors in the active site with high affinity and a 1:1 stoichiometric ratio (<a href="./references#CD011782-bbs2-0073" title="SiegalDM , CurnutteJT , ConnollySJ , LuG , ConleyPB , WiensBL , et al. Andexanet Alfa for the reversal of Factor Xa inhibitor activity. New England Journal of Medicine2015;373(25):2413‐24. ">Siegal 2015</a>). Andexanet alfa has been proven to be effective in reversing the anti‐factor activity of apixaban and rivaroxaban (<a href="./references#CD011782-bbs2-0073" title="SiegalDM , CurnutteJT , ConnollySJ , LuG , ConleyPB , WiensBL , et al. Andexanet Alfa for the reversal of Factor Xa inhibitor activity. New England Journal of Medicine2015;373(25):2413‐24. ">Siegal 2015</a>), and is therefore a promising antidote to fondaparinux. </p> <p>Together, this evidence could change practice worldwide. Fondaparinux appears to present a more favourable balance of efficacy and harms. Unfortunately, the incidence of heparin‐induced thrombocytopenia, a dangerous harm outcome relatively common with the standard treatment of DVT, was not reported, which prevents us from making any further conclusions. Given the combined more convenient dosage and economical advantages, our review supports the development of further research exploring fondaparinux as an alternative to heparins. </p> </section> <h3 class="title" id="CD011782-sec-0149">Implications for research</h3> <section id="CD011782-sec-0149"> <p>Our review showed that the pentasaccharide fondaparinux appears to be an alternative to conventional anticoagulants for the treatment of DVT. Evidence regarding obese patients, people with cancer, and people receiving outpatient care were derived from subgroup analysis with inherited limitations, thus demanding further and more robust research. </p> <p>The pharmaceutical industry suspended research on the pentasaccharides idraparinux and idrabiotaparinux during the development of the phase III trials in 2009. Prior to the conclusion of this review, we wondered whether this could have been an early decision or whether further data on harmful outcomes have been unpublished. Nevertheless, our results confirm the lack of treatment benefits of these agents in comparison to standard treatment, and no further research is encouraged. </p> <p>Treatment with fondaparinux does not have an antidote to reverse the anticoagulant effect, which is a matter of concern to clinicians and patients. A recombinant human factor Xa protein, andexanet, is under review by the FDA and is a promising agent to reverse the anti‐factor activity of fondaparinux (<a href="./references#CD011782-bbs2-0073" title="SiegalDM , CurnutteJT , ConnollySJ , LuG , ConleyPB , WiensBL , et al. Andexanet Alfa for the reversal of Factor Xa inhibitor activity. New England Journal of Medicine2015;373(25):2413‐24. ">Siegal 2015</a>). An injection of 90 mcg of recombinant factor VIIa has also shown potential in reversing the anticoagulant effect in volunteers who used 10 mg of fondaparinux in emergency situations (<a href="./references#CD011782-bbs2-0018" title="BijsterveldNR , MoonsAH , BoekholdtSM , vanAkenBE , FennemaH , PetersRJ , et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation2002;106(20):2550‐4. ">Bijsterveld 2002</a>). The expectation of near availability of an antidote to the anticoagulation effect of fondaparinux is likely to change research and practice of thromboembolic disease. </p> <p>Thromboembolic disease is a severe and potentially fatal condition. Its aetiology is multifactorial, its clinical presentation has a myriad of peculiarities that still deserve continuing improvements, and the search continues for an ideal anticoagulant agent. Further randomised studies are encouraged to devote special attention to (i) collecting high‐quality data to validate fondaparinux as a treatment option to heparin‐induced thrombocytopenia and (ii) investigating the benefits and harms of the treatment of DVT in people at higher risk of thromboembolic disease, such as people with cancer. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011782-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011782-sec-0022"></div> <div class="table" id="CD011782-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fondaparinux plus vitamin K antagonist compared to standard therapy for the treatment of deep vein thrombosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fondaparinux plus vitamin K antagonist compared to standard therapy for the treatment of deep vein thrombosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people &gt; 18 years of age with a diagnosed deep vein thrombosis<br/> <b>Setting:</b> hospitalised and non‐hospitalised patients<br/> <b>Intervention:</b> fondaparinux plus vitamin K antagonist<br/> <b>Comparison:</b> standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fondaparinux plus vitamin K antagonist</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/> (0.43 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2658<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (18 to 61) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment<br/> Follow‐up: 5 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.15<br/> (0.39 to 3.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2645<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In contrast with other harm outcomes, bleeding was not subjected to detection bias.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (4 to 37) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.64 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2645<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In contrast with other harm outcomes, bleeding was not subjected to detection bias.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (15 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.45 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2645<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (15 to 65) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin‐induced thrombocytopenia ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>7 participants in each treatment group of the MATISSE‐DVT trial developed thrombocytopenia. This represents a frequency of thrombocytopenia approximately equal to 0.64% in both groups. None of the thrombocytopenic participants were reported as having developed heparin‐induced thrombocytopenia antibodies, and none of the cases were associated with thromboembolism events. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The MATISSE‐DVT trial reported no definition of thrombocytopenia and a non‐standard definition of heparin‐induced thrombocytopenia. It was stated that laboratory tests were used in the diagnosis of heparin‐induced thrombocytopenia, but the report related to these tests was incomplete. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All harmful effects<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.76 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2192<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000<br/> (340 to 416) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*We calculated the assumed risk of the standard therapy group from the average risk in the standard therapy group (i.e. the number of participants with events divided by total number of participants of the standard therapy group included in the meta‐analysis). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect,<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to unclear risk of bias in multiple criteria (selection bias, performance bias, and attrition bias related to efficacy outcomes) and high risk of attrition bias related to efficacy outcomes in one study.<br/> <sup>2</sup>Downgraded for high risk of detection bias related to harm outcomes.<br/> <sup>3</sup>Downgraded twice for high risk of detection and attrition bias related to harm outcomes.<br/> <sup>4</sup>Downgraded for imprecision caused by single study and small number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011782-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Idrabiotaparinux compared to idraparinux for the treatment of deep vein thrombosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Idrabiotaparinux compared to idraparinux for the treatment of deep vein thrombosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people &gt; 18 years of age with a diagnosed deep vein thrombosis<br/> <b>Setting:</b> hospitalised and non‐hospitalised patients<br/> <b>Intervention:</b> idrabiotaparinux<br/> <b>Comparison:</b> idraparinux </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with idraparinux</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with idrabiotaparinux</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.72<br/> (0.31 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>757<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (10 to 55) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding during the initial treatment ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding during the initial treatment period was not reported in the single included study in this comparison. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21<br/> (0.06 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>755<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>While bleeding was considered a main harm outcome, it was diagnosed by a committee unaware of treatment assignment and was therefore judged as not influenced by detection bias. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/> (2 to 27) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/> (0.18 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>757<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (6 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin‐induced thrombocytopenia ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition for or data on thrombocytopenia or heparin‐induced thrombocytopenia</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All harmful effects<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.83 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>757<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>685 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>630 per 1000<br/> (568 to 698) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*We calculated the assumed risk of the idraparinux group from the average risk in the idraparinux group (i.e. the number of participants with events divided by total number of participants of the idraparinux group included in the meta‐analysis). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to high risk of attrition bias related to efficacy outcome.<br/> <sup>2</sup>Downgraded due to imprecision caused by single study and small number of events.<br/> <sup>3</sup>Downgraded due to high risk of attrition bias related to harm outcome.<br/> <sup>4</sup>Downgraded twice due to high risk of detection and attrition bias related to harm outcome. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011782-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Low molecular weight heparin and idraparinux compared to standard therapy for the treatment of deep vein thrombosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low molecular weight heparin (LMWH) and idraparinux compared to standard therapy for the treatment of deep vein thrombosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people &gt; 18 years of age with a diagnosed deep vein thrombosis<br/> <b>Setting:</b> hospitalised and non‐hospitalised patients<br/> <b>Intervention:</b> LMWH and idraparinux<br/> <b>Comparison:</b> standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LMWH and idraparinux</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/> assessed with: idraparinux 10 mg<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.51<br/> (0.26 to 8.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>263<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (4 to 135) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment<br/> Follow‐up: 5 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment period was not reported in the single included study in this comparison. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/> assessed with: all doses<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.76<br/> (0.50 to 28.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>659<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (4 to 214) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>A total of 7 cases (of 527 participants) were reported in the group receiving idraparinux after LMWH and zero deaths (of 132 participants) in the group receiving standard therapy. Zero events in the group receiving standard therapy prevented us from conducting a pooled analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study providing data for this comparison was deemed at high risk of bias for incomplete outcome data. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heparin‐induced thrombocytopenia<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The published report stated that no events of heparin‐induced thrombocytopenia were observed, although without providing any details on how it was assessed and diagnosed. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All harmful effects<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data on harmful effects were not provided for any of the treatment groups.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The published report stated that "adverse effects were distributed similarly between the groups", but reported an increase in the alanine aminotransferase levels in 15% of participants during the initial LMWH phase. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*We calculated the assumed risk of the standard group from the average risk in the standard therapy group (i.e. the number of participants with events divided by total number of participants of the standard therapy group included in the meta‐analysis). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice due to unclear risk of selection bias and high risk of performance and attrition bias related to efficacy outcomes.<br/> <sup>2</sup>Downgraded due to imprecision caused by single study and small number of participants and events.<br/> <sup>3</sup>Downgraded twice due to high risk of detection and attrition bias related to harm outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011782-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Idraparinux compared to standard therapy for the treatment of deep vein thrombosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Idraparinux compared to standard therapy for the treatment of deep vein thrombosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people &gt; 18 years of age with a diagnosed deep vein thrombosis<br/> <b>Setting:</b> hospitalised and non‐hospitalised patients<br/> <b>Intervention:</b> idraparinux<br/> <b>Comparison:</b> standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with idraparinux</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.64 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2904<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (19 to 44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment<br/> Follow‐up: 5 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment period was not reported in the single included study in this comparison. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.34 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2904<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/> (4 to 17) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/> (0.69 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2904<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (14 to 37) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heparin‐induced thrombocytopenia<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No definition for or data on thrombocytopenia and heparin‐induced thrombocytopenia were reported. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All harmful effects<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2904<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>874 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000<br/> (874 to 926) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*We calculated the assumed risk of the standard therapy group from the average risk in the standard therapy group (i.e. the number of participants with events divided by total number of participants of the standard therapy group included in the meta‐analysis). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to high risk of performance bias.<br/> <sup>2</sup>Downgraded due to imprecision caused by single study and small number of events.<br/> <sup>3</sup>Downgraded due to high risk of attrition bias related to harm outcomes. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011782-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011782-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011782-sec-0164">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011782-sec-0023"></div> <section id="CD011782-sec-0024"> <h3 class="title" id="CD011782-sec-0024">Description of the condition</h3> <p>Deep vein thrombosis (DVT) is a severe disorder caused by acute formation of a clot or thrombus in the deep vein system, typically in the lower extremities of the body. It results in impaired venous blood flow, which may in turn lead to leg swelling, pain, and with propagation of the clot, to pulmonary embolism and death. Clots that form in the deep veins of the lower extremities are more likely to dislodge from the limbs and reach the pulmonary vasculature. </p> <p>Together, DVT and pulmonary embolism constitute venous thromboembolism (VTE). Between 2007 and 2009, an average 547,596 adults aged 18 years or older were hospitalised with VTE annually in the United States, with confirmed DVT in an estimated annual average of 348,558 hospitalisations (<a href="./references#CD011782-bbs2-0023" title="Centers for Disease Control and Prevention. Venous thromboembolism in adult hospitalizations ‐ United States 2007‐2009. Morbidity and Mortality Weekly Report2012;61(22):401‐4. ">Centers for Disease Control and Prevention 2012</a>). As noted in <a href="./references#CD011782-bbs2-0042" title="GoldhaberSZ , BounameauxH . Pulmonary embolism and deep vein thrombosis. Lancet2012;379(9828):1835‐46. ">Goldhaber 2012</a>, recurrence is common after a first episode of DVT or pulmonary embolism. <a href="./references#CD011782-bbs2-0037" title="FowkesFJ , PriceJF , FowkesFG . Incidence of diagnosed deep vein thrombosis in the general population: systematic review. European Journal of Vascular and Endovascular Surgery2003;25(1):1‐5. ">Fowkes 2003</a> described a steep increase in the incidence of DVT with age, from 2 to 3 per 10,000 in adults aged 30 to 49 years to 20 per 10,000 in adults aged 70 to 79 years. </p> <p>Deep vein thrombosis may be diagnosed by one of three objective tests: bilateral ascending contrast venography, duplex ultrasound, or colour duplex ultrasound (<a href="./references#CD011782-bbs2-0030" title="European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for prophylaxis of high intra‐ and post‐operative venous thromboembolic risk. CPMP/EWP/707/98 Rev.1 corr. London, 15 November 2007. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003301.pdf (accessed prior to 4 November 2017). ">EMA 2007b</a>). Standard treatment is based on antithrombotic therapy (<a href="./references#CD011782-bbs2-0054" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e419S‐94S. ">Kearon 2012</a>), initially with parenteral administration (administration through intravenous or subcutaneous injections) of unfractionated heparin or low molecular weight heparins (LMWH) for five to seven days, then subsequent long‐term oral vitamin K antagonists (e.g. warfarin) therapy (<a href="./references#CD011782-bbs2-0034" title="ErkensPM , PrinsMH . Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews2010, Issue 9. [DOI: 10.1002/14651858.CD001100.pub3] ">Erkens 2010</a>). To manage the ideal dose of vitamin K antagonists, it is necessary to reach a therapeutic international normalised ratio (INR) range of 2.0 to 3.0 before the end of heparin treatment (<a href="./references#CD011782-bbs2-0059" title="McRaeSJ , GinsbergJS . Initial treatment of venous thromboembolism. Circulation2004;110(9 Suppl 1):I3‐9. ">McRae 2004</a>). In the first three months of therapy, the goal of DVT treatment is to prevent the extension and embolisation of the thrombus so as to minimise late local effects of venous thrombosis. In people with pulmonary embolism, the goal is to prevent potentially fatal recurrence. After the third month, the use of continuous anticoagulation therapy is used as a prophylactic measure to prevent late recurrence. However, therapy with warfarin may be problematic and requires monitoring, since individual response to the medicine may vary. In addition, haemorrhagic complications (major and clinically relevant) are a major concern associated with warfarin treatment, and may occur at virtually any site. Indeed, the haemorrhagic risk of warfarin and the required laboratory control remain the Achilles’ heel of vitamin K antagonist management. </p> </section> <section id="CD011782-sec-0025"> <h3 class="title" id="CD011782-sec-0025">Description of the intervention</h3> <p>New anticoagulants have recently been developed aiming to improve the profile of harms and efficacy outcomes of DVT treatment. Among them, synthetic pentasaccharides have been modelled on the sequence of the heparin responsible for the binding of a particular coagulation protein, which leads to inhibition of the coagulation cascade and to clot formation and growth (<a href="./references#CD011782-bbs2-0080" title="vanBoeckelCAA , PetitouM . The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angewandte Chemie International Edition in English1993;32(12):1671–90. ">van Boeckel 1993</a>). Pentasaccharides are, therefore, synthetic and selective anticoagulant drugs, in contrast with heparins, which are obtained from animal sources. More specifically, pentasaccharides act indirectly, inhibiting the activated factor X (Xa), thus interrupting the blood coagulation cascade and inhibiting both thrombin formation and thrombus development (<a href="./references#CD011782-bbs2-0029" title="European Medicines Agency. Scientific discussion. Product name: Arixtra. EMEA/H/C/403/II/24. London, 29 August 2007. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Scientific_Discussion_‐_Variation/human/000403/WC500027742.pdf (accessed 2 September 2014). ">EMA 2007a</a>; <a href="./references#CD011782-bbs2-0031" title="European Medicines Agency. EPAR summary for the public. Arixtra ‐ fondaparinux sodium. EMA/496403/2010. EMEA/H/C/000403. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000403/WC500027736.pdf (accessed 30 October 2014). ">EMA 2010</a>). Factor X is located at the starting point of the common pathway of the extrinsic and intrinsic coagulation systems and therefore plays a central role in thrombin generation (<a href="./references#CD011782-bbs2-0014" title="BauerKA . New pentasaccharides for prophylaxis of deep vein thrombosis. Chest2003;124(6 Suppl):364S–70S. ">Bauer 2003</a>). </p> <p>The advantages attributed to pentasaccharides include a more convenient dosing regimen, a more predictable anticoagulant response, and no need for laboratory monitoring (<a href="./references#CD011782-bbs2-0014" title="BauerKA . New pentasaccharides for prophylaxis of deep vein thrombosis. Chest2003;124(6 Suppl):364S–70S. ">Bauer 2003</a>; <a href="./references#CD011782-bbs2-0061" title="NutescuEA , ShapiroNL , ChevalierA , AminA . A pharmacologic overview of current and emerging anticoagulants. Cleveland Clinic Journal of Medicine2005;72(1):S2‐6. ">Nutescu 2005</a>; <a href="./references#CD011782-bbs2-0084" title="WeitzJI . New anticoagulants for treatment of venous thromboembolism. Circulation2004;110(9 Suppl 1):I19‐26. ">Weitz 2004</a>). In addition, because pentasaccharides are not metabolised in the liver, drug interactions may be reduced. Similarly, adverse reactions that often occur with heparins and vitamin K antagonists, such as bleeding and heparin‐induced thrombocytopenia, are expected to be reduced (<a href="./references#CD011782-bbs2-0061" title="NutescuEA , ShapiroNL , ChevalierA , AminA . A pharmacologic overview of current and emerging anticoagulants. Cleveland Clinic Journal of Medicine2005;72(1):S2‐6. ">Nutescu 2005</a>). However, other limitations stand for pentasaccharides: </p> <p> <ul id="CD011782-list-0001"> <li> <p>currently, there is no antidote to reverse the effect of pentasaccharides (except for idrabiotaparinux) if the patient presents any adverse bleeding to treatment or requires an invasive procedure (<a href="./references#CD011782-bbs2-0040" title="GerotziafasGT , DepasseF , ChakrounT , SamamaMM , ElalamyY . Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thrombosis and Haemostasis2004;91(3):531–7. ">Gerotziafas 2004</a>); </p> </li> <li> <p>the risk‐benefit balance of this class of medicines is still under question; and</p> </li> <li> <p>financial costs may have significant impact on treatment.</p> </li> </ul> </p> </section> <section id="CD011782-sec-0026"> <h3 class="title" id="CD011782-sec-0026">How the intervention might work</h3> <p>The first synthetic pentasaccharide compound granted approval for commercialisation was fondaparinux (approved in 2001 in the United States and 2002 in Europe). Preliminary data have shown that fondaparinux was at least as efficacious as enoxaparin, a LMWH, with similar rates of death or clinically relevant bleeding for VTE prophylaxis following orthopaedic surgery (<a href="./references#CD011782-bbs2-0033" title="ErikssonBI , BauerKA , LassenMR , TurpieAGG . Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip‐fracture surgery. New England Medical Journal2001;345(18):1298‐304. ">Eriksson 2001</a>; <a href="./references#CD011782-bbs2-0056" title="LassenMR , BauerKA , ErikssonBI , TurpieAGG . Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip‐replacement surgery: a randomised double‐blind comparison. Lancet2002;359(9319):1715–20. ">Lassen 2002</a>). Fondaparinux is currently widely recommended for VTE prophylaxis (<a href="./references#CD011782-bbs2-0054" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e419S‐94S. ">Kearon 2012</a>; <a href="./references#CD011782-bbs2-0068" title="ReynoldsNA , PerryCM , ScottLJ . Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs2004;64(14):1575‐96. ">Reynolds 2004</a>), having been approved for VTE prophylaxis in a number of different medical interventions. However, questions remain regarding its effectiveness and harms in comparison with LMWHs. Furthermore, concerns regarding serious adverse drug reactions with fondaparinux, including bleeding, have prompted pharmacovigilance alerts and labelling changes since its approval (<a href="./references#CD011782-bbs2-0036" title="USFood , DrugAdministration . Arixtra (fondaparinux sodium) injection. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) ‐ August 2009. www.fda.gov/Safety/MedWatch/SafetyInformation/ucm182229.htm (accessed 5 September 2009). ">FDA 2009</a>; <a href="./references#CD011782-bbs2-0065" title="Fondaparinux: new indication but still no clear advantage. Prescrire International2006;15(83):101. ">Prescrire 2006</a>; <a href="./references#CD011782-bbs2-0066" title="In France, healthcare products are involved in about half of all serious adverse events related to healthcare. Prescrire International2012;21(125):68. ">Prescrire 2012</a>). </p> <p>Fondaparinux binds selectively to antithrombin, catalysing factor Xa inhibition. It expresses an elevated affinity for antithrombin, and this specific activity leads to lack of variability in anticoagulation action (<a href="./references#CD011782-bbs2-0039" title="GarciaDA , BaglinTP , WeitzJI , SamamaMM . Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e24S‐43S. ">Garcia 2012</a>). Even though the administration route is still a limitation – pentasaccharides can only be administered parenterally – fondaparinux exhibits a longer half‐life (17 hours) in comparison with heparins, which determines a more convenient dosage once a day (<a href="./references#CD011782-bbs2-0027" title="DonatF , DuretJP , SantoniA , CariouR , NecciariJ , MagnaniH , et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clinical Pharmacokinetic2002;41(Suppl 2):1‐9. ">Donat 2002</a>). Fondaparinux does not bind to platelets, and so does not cause heparin‐induced thrombocytopenia (<a href="./references#CD011782-bbs2-0068" title="ReynoldsNA , PerryCM , ScottLJ . Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs2004;64(14):1575‐96. ">Reynolds 2004</a>), but renal clearance remains a limitation, contraindicating its use in people with severe renal insufficiency (creatinine clearance less than 20 mL/min). </p> <p>In addition to fondaparinux, other pentasaccharides include idraparinux and idrabiotaparinux, forms of pentasaccharides that have longer half‐lives (80 to 130 hours). The pharmacokinetic properties of idraparinux were designed to allow weekly dosing by subcutaneous injection without coagulation monitoring (<a href="./references#CD011782-bbs2-0078" title="The PERSIST Investigators. A novel long‐acting synthetic factorXa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis: a phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ">The PERSIST Investigators 2004</a>). Idrabiotaparinux is identical to idraparinux but has biotin incorporated to its molecule, so that anticoagulant action can be reversed by avidin injection (<a href="./references#CD011782-bbs2-0062" title="PatyI , TrelluM , DestorsJM , CortezP , BoelleE , SanderinkG . Reversibility of the anti‐FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. Journal of Thrombosis and Haemostasis2010;8(4):722‐9. ">Paty 2010</a>; <a href="./references#CD011782-bbs2-0079" title="TrelluM , FauJB , CortezP , ChengS , PatyI , BoëlleE , et al. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis. British Journal of Clinical Pharmacology2013;75(5):1255‐64. ">Trellu 2013</a>). However, the development of both idraparinux and idrabiotaparinux was discontinued during phase III trials. A higher risk of bleeding after treatment of VTE and lower efficacy in the treatment of pulmonary embolism compared to standard treatment (enoxaparin followed by warfarin) appear to be the major problems justifying the pharmaceutical industry statement that these compounds do not appear to be able to bring significant improvement in the care of patients (<a href="./references#CD011782-bbs2-0047" title="HarenbergJ , VukojevicY , MikusG , JoergI , WeissC . Long elimination half‐life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. Journal of Thrombosis and Haemostasis2008;6(5):890‐2. ">Harenberg 2008</a>; <a href="./references#CD011782-bbs2-0070" title="Sanofi‐Aventis . Press release 2009. Discontinuation of development for idrabiotaparinux in atrial fibrillation. 21 December 2009. www.sanofi.se/l/se/sv/layout.jsp?cnt=94401A59‐49CC‐406D‐BF31‐4C46AEDF511F (accessed 5 September 2014). ">Sanofi‐Aventis 2009</a>; <a href="./references#CD011782-bbs2-0081" title="van Gogh Investigators, BullerHR , CohenAT , DavidsonB , DecoususH , GallusAS , et al. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. ">van Gogh Investigators 2007</a>). Nevertheless, a recent non‐Cochrane Review noted that the available evidence is still not sufficient to clarify whether or not idraparinux and idrabiotaparinux are as effective and safe as the standard warfarin treatment for VTE treatment (<a href="./references#CD011782-bbs2-0074" title="SongY , LiX , PavithraS , LiD . Idraparinux or idrabiotaparinux for long‐term venous thromboembolism treatment: a systematic review and meta‐analysis of randomized controlled trials. PLoS ONE2013;8(11):e78972. ">Song 2013</a>). </p> </section> <section id="CD011782-sec-0027"> <h3 class="title" id="CD011782-sec-0027">Why it is important to do this review</h3> <p>The traditional forms of anticoagulation therapy may be associated with major limitations in terms of laboratory monitoring, complications induced by adverse reactions, drug interactions, and even dietary aspects (e.g. vitamin K antagonists' interaction with food containing elevated levels of vitamin K). Unfractionated heparin is administered exclusively via parenteral route and requires laboratory monitoring of activated partial thromboplastin time and platelet count due to the risk of heparin‐induced thrombocytopenia (<a href="./references#CD011782-bbs2-0051" title="JunqueiraDR , ZorzelaLM , PeriniE . Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD007557.pub3] ">Junqueira 2017</a>). Since heparins are produced from biological sources, they are also sensitive to contamination (<a href="./references#CD011782-bbs2-0019" title="BlossomDB , KallenAJ , PatelPR , ElwardA , RobinsonL , GaoG , et al. Outbreak of adverse reactions associated with contaminated heparin. New England Journal of Medicine2008;359(25):2674‐84. ">Blossom 2008</a>). </p> <p>While Vitamin K antagonists can be administered orally, these agents also require strict laboratory monitoring to ensure that the desired anticoagulation effect occurs during the therapeutic interval. Additional limitations of vitamin K antagonists include interactions with drugs and food, adverse reactions such as skin necrosis, and teratogenic potential (<a href="./references#CD011782-bbs2-0015" title="BauerKA . New oral anticoagulants in development: potential for improved safety profiles. Reviews in Neurological Diseases2010;7(1):1‐8. ">Bauer 2010</a>; <a href="./references#CD011782-bbs2-0016" title="BenmiraS , BandaZK , BhattacharyaV . Old versus new anticoagulants: focus on pharmacology. Recent Patents on Cardiovascular Drug Discovery2010;5(2):120‐37. ">Benmira 2010</a>; <a href="./references#CD011782-bbs2-0038" title="GarciaD . Novel anticoagulants and the future of anticoagulation. Thrombosis Research2009;123 Suppl 4:S50‐5. ">Garcia 2009</a>; <a href="./references#CD011782-bbs2-0046" title="HaasS . New oral Xa and IIa inhibitors: updates on clinical trial results. Journal of Thrombosis and Thrombolysis2008;25(1):52‐60. ">Haas 2008</a>; <a href="./references#CD011782-bbs2-0057" title="LauxV , PerzbornE , HeitmeierS , vonDegenfeldG , Dittrich‐WengenrothE , BuchmullerA , et al. Direct inhibitors of coagulation proteins ‐ the end of the heparin and low‐molecular‐weight heparin era for anticoagulant therapy?. Thrombosis and Haemostasis2009;102(5):892‐9. ">Laux 2009</a>; <a href="./references#CD011782-bbs2-0075" title="SpyropoulosAC . Brave new world: the current and future use of novel anticoagulants. Thrombosis Research2008;123 Suppl 1:S29‐35. ">Spyropoulos 2008</a>). </p> <p>Even though monitoring is not required for dose adjustment of LMWH, making home treatment possible (<a href="./references#CD011782-bbs2-0021" title="BullerHR , AgnelliG , HullRD , HyersTM , PrinsMH , RaskobGE . Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004;126(3 Suppl):401S‐28S. ">Buller 2004</a>), some clinically relevant aspects have not been fully elucidated. For instance, different types of LMWH (enoxaparin, tinzaparin, etc.) present with different pharmacokinetics properties and thus cannot be readily interchanged, and whether one or another type of heparin is available during the course of a treatment may not be a clinical decision. In countries where public health systems have financial imitations, the type of heparin available depends on costs and may vary on monthly, or sometimes weekly, basis. Weight adjustment doses required for LMWHs may also be a limitation in areas with limited resources and in trauma settings. There is conflicting evidence regarding the advantage of one or two daily applications given that the anticoagulant effect of LMWHs may not always be anticipated (<a href="./references#CD011782-bbs2-0020" title="BreddinHK , Hach‐WunderleV , NakovR , KakkarVV , CORTES Investigators. Effects of a low‐molecular‐weight heparin on thrombus regression and recurrent thromboembolism in patients with deep‐vein thrombosis. New England Journal of Medicine2001;344(9):626‐31. [DOI: 10.1056/NEJM200103013440902] ">Breddin 2001</a>; <a href="./references#CD011782-bbs2-0060" title="MerliG , SpiroTE , OlssonCG , AbildgaardU , DavidsonBL , EldorA , et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Annals of Internal Medicine2001;134(3):191‐202. ">Merli 2001</a>), and the best dose for people with renal failure has not yet been fully defined (<a href="./references#CD011782-bbs2-0024" title="ColletJP , MontalescotG , ChoussatR , LisonL , AnkriA . Enoxaparin in unstable angina patients with renal failure. International Journal of Cardiology2001;80(1):81‐2. ">Collet 2001</a>; <a href="./references#CD011782-bbs2-0069" title="SanderinkGJ , GuimartCG , OzouxML , JariwalaNU , ShuklaUA , BoutouyrieBX . Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thrombosis Research2002;105(3):225‐31. ">Sanderink 2002</a>). These limitations, together with the motivation for the development of more efficacious and convenient anticoagulants drugs, have driven the search for new agents. </p> <p>Determining the efficacy and harms of pentasaccharides is therefore important to provide useful information to improve the treatment of people with DVT. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011782-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011782-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011782-sec-0169">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011782-sec-0028"></div> <p>To assess the efficacy and harms of pentasaccharides for the treatment of deep vein thrombosis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011782-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011782-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011782-sec-0170">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011782-sec-0029"></div> <section id="CD011782-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011782-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> </section> <section id="CD011782-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies reporting on participants older than 18 years of age with DVT involving popliteal, femoral, iliac veins, or calf veins. Diagnosis of DVT should be confirmed by at least one standard imaging technique (venography or duplex venous ultrasonography). </p> </section> <section id="CD011782-sec-0033"> <h4 class="title">Types of interventions</h4> <p>The treatment of interest was pentasaccharide anticoagulant therapy for DVT.</p> <p>Despite the development of idraparinux and idrabiotaparinux having been discontinued in 2009 due to safety issues, a non‐Cochrane Review has noted that the available evidence is still insufficient to clarify whether or not these two medications are as effective and safe as warfarin for the treatment of VTE (<a href="./references#CD011782-bbs2-0074" title="SongY , LiX , PavithraS , LiD . Idraparinux or idrabiotaparinux for long‐term venous thromboembolism treatment: a systematic review and meta‐analysis of randomized controlled trials. PLoS ONE2013;8(11):e78972. ">Song 2013</a>). We have therefore included idraparinux and idrabiotaparinux in the review to ensure the results are as comprehensive as possible. </p> <p>We planned to compare our treatment intervention of interest to standard therapy (LMWHs, unfractionated heparin, or vitamin K antagonists, e.g. warfarin) or other treatments identified in the RCTs (e.g. placebo, other anticoagulants). </p> <p>We excluded studies assessing pentasaccharide anticoagulant therapy for the prevention of VTE, as they form part of another Cochrane Review (<a href="./references#CD011782-bbs2-0028" title="DongK , SongY , LiX , DingJ , GaoZ , LuD , et al. Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD005134.pub3] ">Dong 2016</a>). We also did not consider studies investigating the efficacy and harms of pentasaccharide for the treatment of pulmonary embolism to adhere to our review title and protocol. </p> <p>In order to differentiate treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), we considered trials evaluating participants with DVT and PE only if data concerning participants with DVT could be extracted separately. This was important to assure that the results were not mixing outcomes of participants treated for DVT and those treated for PE. </p> </section> <section id="CD011782-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD011782-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011782-list-0002"> <li> <p>Main efficacy outcome:</p> <ul id="CD011782-list-0003"> <li> <p>Any VTE: incidence of symptomatic, recurrent VTE during a six‐month study period. We defined symptomatic, recurrent VTE as objectively documented DVT or pulmonary embolism. </p> </li> </ul> </li> </ul> <ul id="CD011782-list-0004"> <li> <p>Main harm outcome:</p> <ul id="CD011782-list-0005"> <li> <p>Major and clinically relevant bleeding. Major bleeding (as defined by the International Society on Thrombosis and Haemostasis) (<a href="./references#CD011782-bbs2-0072" title="SchulmanS , KearonC . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. Journal of Thrombosis and Haemostasis2005;3(4):692‐4. ">Schulman 2005</a>): </p> <ol id="CD011782-list-0006"> <li> <p>fatal bleeding;</p> </li> <li> <p>symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra‐articular or pericardial bleeding, or intramuscular bleeding progressing to compartment syndrome; </p> </li> <li> <p>bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells; </p> </li> <li> <p>any combination of points 1 to 3.</p> </li> </ol> </li> </ul> </li> </ul> </p> </section> <section id="CD011782-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011782-list-0007"> <li> <p>Efficacy outcomes:</p> <ul id="CD011782-list-0008"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Recurrent DVT: symptomatic DVT confirmed by standard imaging techniques including a new non‐compressible venous segment or a substantial increase (4 mm or more) in thrombus diameter during full compression in a previously abnormal segment on ultrasonography (<a href="./references#CD011782-bbs2-0063" title="PrandoniP , CogoA , BernardiE , VillaltaS , PolistenaP , SimioniP , et al. A simple ultrasound approach for detection of recurrent proximal‐vein thrombosis. Circulation1993;88(4 Pt 1):1730‐5. ">Prandoni 1993</a>; <a href="./references#CD011782-bbs2-0064" title="PrandoniP , LensingAW , PiccioliA , BernardiE , SimioniP , GirolamiB , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood2002;100(10):3484‐8. ">Prandoni 2002</a>), or a new intraluminal filling defect found on venograph. </p> </li> <li> <p>Pulmonary embolism (fatal and non‐fatal): symptomatic pulmonary embolism confirmed by an intraluminal filling defect on computed tomography or pulmonary angiography; a cut‐off vessel of more than 2.5 mm in diameter on pulmonary angiography; a perfusion defect of at least 75% of a segment with corresponding normal ventilation (high‐probability lung scan); non‐diagnostic lung scan associated with new DVT documented by ultrasonography or venography; or pulmonary embolism confirmed by autopsy (<a href="./references#CD011782-bbs2-0021" title="BullerHR , AgnelliG , HullRD , HyersTM , PrinsMH , RaskobGE . Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004;126(3 Suppl):401S‐28S. ">Buller 2004</a>). </p> </li> </ul> </li> <li> <p>Harm outcomes:</p> <ul id="CD011782-list-0009"> <li> <p>Thrombocytopenia (reduction in platelet count above 150 x 10<sup>9</sup>/L). </p> </li> <li> <p>Heparin‐induced thrombocytopenia syndrome defined as a relative reduction in platelet count of about 50% (even if the platelet count at its lowest remains above 150 x 10<sup>9</sup>/L) occurring within 5 to 14 days after the start of heparin therapy (<a href="./references#CD011782-bbs2-0082" title="WarkentinTE , RobertsRS , HirshJ , KeltonJG . An improved definition of immune heparin‐induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine2003;163(20):2518–24. ">Warkentin 2003</a>). Clinically suspected cases of heparin‐induced thrombocytopenia syndrome should have diagnosis confirmed through functional or immunological laboratory tests to detect platelet activation induced by anti‐platelet factor 4 antibodies (<a href="./references#CD011782-bbs2-0055" title="KeelingD , DavidsonS , WatsonH , Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. The management of heparin‐induced thrombocytopenia. British Journal of Haematology2006;133(3):259–69. ">Keeling 2006</a>). </p> </li> <li> <p>All other adverse effects induced by the treatments, including those leading to drop out from the trial including but not limited to anaemia, insomnia, increased wound drainage, hypokalaemia, dizziness, hypotension, confusion, bullous eruption, haematoma, increase in transaminases, or dermatological reactions. </p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD011782-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed the electronic searches with no restrictions on language.</p> <section id="CD011782-sec-0038"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist (CIS) searched the following databases for relevant trials: </p> <p> <ul id="CD011782-list-0010"> <li> <p>the Cochrane Vascular Specialised Register (22 March 2017);</p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 2) (searched 22 March 2017) via the Cochrane Register of Studies Online. </p> </li> </ul> </p> <p>See <a href="./appendices#CD011782-sec-0153">Appendix 1</a> for details of the search strategy used to search CENTRAL. </p> <p>The Cochrane Vascular Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE Ovid, Embase Ovid, CINAHL (Cumulative Index to Nursing and Allied Health Literature), AMED (Allied and Complementary Medicine Database), and through handsearching relevant journals. The full list of the databases, journals, and conference proceedings that have been searched, as well as the search strategies used, are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Vascular module in the Cochrane Library (<a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>). </p> <p>In addition, the CIS searched the following trial registries (22 March 2017) for details of ongoing or unpublished studies: </p> <p> <ul id="CD011782-list-0011"> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>); </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>). </p> </li> </ul> </p> <p>See <a href="./appendices#CD011782-sec-0154">Appendix 2</a> for details of the trials registries searches. </p> </section> <section id="CD011782-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We checked citations of included studies to identify additional studies not retrieved in the electronic search. We also searched the website of the pharmaceutical company GlaxoSmithKline for non‐reported trials of fondaparinux. </p> </section> </section> <section id="CD011782-sec-0040"> <h3 class="title" id="CD011782-sec-0040">Data collection and analysis</h3> <section id="CD011782-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GB and DJ) independently screened titles and abstracts of the identified citations for potential eligibility. We excluded studies clearly not relevant (e.g. studies investigating the addition of vena cava filter to anticoagulation with fondaparinux) at this stage, although we retained studies that could have included relevant data or information on other studies. We retrieved the full texts of articles judged to be potentially eligible by at least one review author, and then independently screened the full‐text articles for eligibility using a standardised study selection form. Disagreement were resolved by consensus. </p> <p>Where there was insufficient information available to decide whether a study met the eligibility criteria, we attempted to contact the study authors. </p> </section> <section id="CD011782-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (GB, MS, and DJ) performed data extraction using a standardised data extraction form. Where we identified more than one report of a study, we extracted data from the primary report and checked discrepancies against reports. Data for reports of subgroup populations were extracted separately but linked to the primary study report. We considered trials evaluating people with DVT and PE if data concerning participants with DVT could be extracted separately. Disagreements were resolved by consensus. </p> </section> <section id="CD011782-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We planned to assess the risk of bias in included studies using Cochrane's 'Risk of bias' tool (<a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), which contains the following domains: </p> <p> <ul id="CD011782-list-0012"> <li> <p>sequence generation (selection bias);</p> </li> <li> <p>allocation sequence concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective outcome reporting (reporting bias);</p> </li> <li> <p>other bias.</p> </li> </ul> </p> <p>At the review stage, we judged it appropriate to assess the risk of bias for some domains separately for different groups/outcomes in accordance with the Cochrane's 'Risk of bias' tool (<a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We therefore assessed: </p> <p> <ul id="CD011782-list-0013"> <li> <p>blinding of participants and personnel (performance bias) separately for (i) participants and (ii) personnel; </p> </li> <li> <p>blinding of outcome assessment (detection bias) separately for (i) efficacy outcomes and (ii) harm outcomes; </p> </li> <li> <p>incomplete outcome data (attrition bias) separately for (i) primary efficacy outcome and (ii) harm outcomes. </p> </li> </ul> </p> <p>We judged risk of bias in each domain as high, low, or unclear, and provided a statement to support each of our judgements in accordance with the referenced tool. </p> </section> <section id="CD011782-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>Our primary and secondary outcomes were dichotomous variables. For primary efficacy outcomes, we calculated the risk ratio (RR) with 95% confidence intervals (CIs). For harm outcomes, we reported absolute risks (AR, or incidence) and RR with 95% CIs. Groups with zero outcomes were reported but not considered in the analyses of the measures of the treatment effect because most of the estimates of effect may be problematic in a situation of zero events, and analysis of relative effect in these situations could bias the study estimates (<a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>In our protocol, we planned to calculate risk differences, but since relative effect measures are considered to be more consistent than absolute measures (<a href="./references#CD011782-bbs2-0026" title="DeeksJJ . Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21:1575‐600. ">Deeks 2002</a>; <a href="./references#CD011782-bbs2-0032" title="EngelsEA , SchmidCH , TerrinN , OlkinI , LauJ . Heterogeneity and statistical significance in meta‐analysis: an empirical study of 125 meta‐analyses. Statistics in Medicine2000;19:1707‐28. ">Engels 2000</a>), we only calculated the RR. </p> </section> <section id="CD011782-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant.</p> </section> <section id="CD011782-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We based our data analysis on intention‐to‐treat data from the individual clinical trials thereby accounting for dropout data. We attempted to obtain information regarding dropouts, withdrawals, and other missing data from the study authors. In the event that we were unable to obtain these data from the study authors, we analysed the available data and took the missing information into consideration in the 'Risk of bias' analysis. </p> <p>Regarding the analysis of harm outcomes in particular, the included studies analysed only the data of those participants who received at least one dose of the study medication. Although this could be considered a non‐randomised comparison (<a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), we judged it reasonable to measure adverse effects only in those participants who received the intervention (<a href="./references#CD011782-bbs2-0025" title="Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Healthcare. Centre for Reviews and Dissemination, 2009. ">CRD's Guidance 2009</a>). To investigate the potential impact of the missing data on the results, we performed a sensitivity analysis based on the 'worst‐case scenario', that is assuming missing participants had experienced the negative outcome. This was a post hoc analysis. </p> </section> <section id="CD011782-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed methodological heterogeneity between studies using the I<sup>2</sup> statistic for quantification of variability. We also used the Chi<sup>2</sup> test by setting statistical significance at a level of 0.1 to improve power. We undertook a sensitivity analysis whenever a result demonstrated significant heterogeneity (P &lt; 0.10 or an I<sup>2</sup> statistic greater than 50%) (<a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>We planned to assess clinical heterogeneity among the studies qualitatively in order to balance the strength of the evidence gathered (internal validity) with the extent to which the results can be generalised to the clinical practice (external validity). We planned to consider the following categories of external validity information (<a href="./references#CD011782-bbs2-0076" title="StecklerA , McLeroyKR . The importance of external validity. American Journal of Public Health2008;98(1):9‐10. ">Steckler 2008</a>): </p> <p> <ul id="CD011782-list-0014"> <li> <p>study participants and delivering settings;</p> </li> <li> <p>intervention and treatment consistency across settings, staff, and time;</p> </li> <li> <p>impact of the outcomes at population, practitioner, and decision makers level.</p> </li> </ul> </p> </section> <section id="CD011782-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>For each analysis, we planned to use funnel plots to investigate the presence of publication bias (the selective publication of trials with positive findings) among the included studies (<a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We would perform this analysis only if a sufficient number of trials (10 or more) were included in the meta‐analysis, since a funnel plot with fewer than 10 studies has insufficient test power to distinguish chance from real asymmetry. </p> </section> <section id="CD011782-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We entered data into Review Manager 5 software (<a href="./references#CD011782-bbs2-0067" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and one review author (DJ) performed data analysis. We combined the efficacy and harmful effects through a meta‐analysis using a random‐effects model, which we undertook to take into account the between‐study variance. </p> <p>We used a fixed‐effect model to present estimates from single studies, that is analysis performed with data from only one study. </p> </section> <section id="CD011782-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We were able to explore the following sources of heterogeneity through stratifying participants by: </p> <p> <ul id="CD011782-list-0015"> <li> <p>body weight;</p> </li> <li> <p>cancer;</p> </li> <li> <p>outpatient treatment.</p> </li> </ul> </p> <p>Data were not available on the following subgroup characteristics specified in our protocol: </p> <p> <ul id="CD011782-list-0016"> <li> <p>age and sex;</p> </li> <li> <p>different types of heparins and pentasaccharides;</p> </li> <li> <p>different treatment duration;</p> </li> <li> <p>previous VTE;</p> </li> <li> <p>provoked and unprovoked VTE;</p> </li> <li> <p>calf vein DVT;</p> </li> <li> <p>pregnancy;</p> </li> <li> <p>major surgery or trauma in the previous 12 weeks;</p> </li> <li> <p>oestrogen therapy; and</p> </li> <li> <p>thrombophilia (genetic or acquired).</p> </li> </ul> </p> </section> <section id="CD011782-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>If there were an adequate number of studies, we planned to perform a sensitivity analysis to explore causes of heterogeneity and the robustness of the results. We would perform the reanalysis by excluding studies judged to be at high risk of bias and those in which more than 20% of participants were lost to follow‐up. </p> <section id="CD011782-sec-0052"> <h5 class="title">'Summary of findings' table</h5> <p>We presented the main findings of the review concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the main outcomes in a 'Summary of findings' table according to <a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>. </p> <p>We described the following outcomes in the 'Summary of findings' table:</p> <p> <ul id="CD011782-list-0017"> <li> <p>recurrent VTE (at three months' follow‐up);</p> </li> <li> <p>major bleeding (at five days' and three months' follow‐up);</p> </li> <li> <p>all‐cause mortality (at three months' follow‐up);</p> </li> <li> <p>thrombocytopenia (at three months' follow‐up).</p> </li> <li> <p>all harmful effects (at three months' follow‐up).</p> </li> </ul> </p> <p>We planned to include thrombocytopenia in the 'Summary of findings' table, however this outcome was not reported in the majority of the included trials. We included the available information on thrombocytopenia and also included our findings on all harmful outcomes in the 'Summary of findings' table to ensure a complete overview of the evidence. </p> <p>Some studies did not report data on the outcomes at the predefined follow‐up cut‐off. In such cases, we described the follow‐up period closest to the predefined one in the 'Summary of findings' table. </p> <p>We assessed different interventions and comparators and created a 'Summary of findings' table for each comparison included in the <a href="./full#CD011782-sec-0053">Results</a> section. We used GRADEpro GDT software to assist in the preparation of the ‘Summary of findings’ tables (<a href="./references#CD011782-bbs2-0044" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 4 April 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011782-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011782-sec-0053"></div> <section id="CD011782-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD011782-sec-0055"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD011782-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011782-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011782-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We identified a total of 734 titles from our electronic searches and one additional title through manually searching the reference lists of relevant studies. Five studies met our inclusion criteria, the results of which were reported in a 18 published titles. </p> </section> <section id="CD011782-sec-0056"> <h4 class="title">Included studies</h4> <p>The five included studies were multicentric parallel RCTs conducted in South America, North America, Europe, Africa, Asia, and Oceania. The 6981 participants included in the studies were mostly adults, within the mean age range of 57 to 62 years, presenting with acute symptomatic DVT. The setting where the participants were recruited was unclear for most of the studies, though due to the nature of DVT, participants were probably identified during hospitalisation. The profile of risk factors for DVT was very heterogeneous among studies but was balanced at baseline. </p> <p>The trials investigated several comparisons between pentasaccharides and standard or alternative therapies. Details of the study methods, participants, interventions, and outcomes are shown in the <a href="./references#CD011782-sec-0162" title="">Characteristics of included studies</a> table and in <a href="#CD011782-tbl-0005">Table 1</a>; <a href="#CD011782-tbl-0006">Table 2</a>; <a href="#CD011782-tbl-0007">Table 3</a>. </p> <div class="table" id="CD011782-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies: Methods</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Countries</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Funding sources</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQUINOX</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006/2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Israel, Italy, Mexico, the Netherlands, New Zealand, Poland, Russia, South Africa, Spain, USA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MATISSE‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000/2001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Russia, South Africa, Spain, Sweden, Switzerland, UK, USA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi and NV Organon</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PERSIST Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999/2001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria, Denmark, Italy, the Netherlands, Poland, Spain, Sweden, UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi and NV Organon</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Rembrandt Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997/1998</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia, Belgium, Canada, France, Italy, New Zealand, Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi and NV Organon</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Van Gogh Trial‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003/2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia, Canada, France, Italy, the Netherlands, UK, USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD011782-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies: Participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of randomised participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (mean)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion criteria</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQUINOX</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0018"> <li> <p>symptomatic pulmonary embolism;</p> </li> <li> <p>active bleeding or high risk of bleeding;</p> </li> <li> <p>creatinine clearance &lt; 30 mL per min;</p> </li> <li> <p>severe hepatic disease;</p> </li> <li> <p>bacterial endocarditis;</p> </li> <li> <p>uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg); </p> </li> <li> <p>known allergy to idraparinux, idrabiotaparinux, or egg proteins;</p> </li> <li> <p>therapeutic doses of LMWH, unfractionated heparin, or fondaparinux given for more than 36 hours before randomisation; </p> </li> <li> <p>initiation of vitamin K antagonist treatment or treatment with thrombolysis, thrombectomy, or a vena cava filter for the current episode of deep vein thrombosis; </p> </li> <li> <p>another indication for prolonged anticoagulant therapy;</p> </li> <li> <p>life expectancy of &lt; 6 months;</p> </li> <li> <p>participation in another pharmacotherapeutic study within the prior 30 days;</p> </li> <li> <p>pregnant women, breastfeeding or premenopausal and not using effective contraceptive measures. </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MATISSE‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0019"> <li> <p>symptomatic pulmonary embolism;</p> </li> <li> <p>received therapeutic doses of LMWH or oral anticoagulants for more than 24 hours;</p> </li> <li> <p>required thrombolysis, thrombectomy, or a vena cava filter;</p> </li> <li> <p>anticoagulant therapy contraindication (e.g. active bleeding, thrombocytopenia (platelet count 100,000 x 10<sup>9</sup>/L)); </p> </li> <li> <p>elevated serum creatinine levels above 177 µmol/L (2 mg/dL);</p> </li> <li> <p>uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg); </p> </li> <li> <p>pregnancy;</p> </li> <li> <p>had a life expectancy &lt; 3 months.</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PERSIST Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>659</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0020"> <li> <p>symptoms for more than 14 days;</p> </li> <li> <p>symptomatic pulmonary embolism;</p> </li> <li> <p>documented DVT within the last 2 years;</p> </li> <li> <p>surgery within the past 10 days;</p> </li> <li> <p>more than 32 hours of therapeutic anticoagulant treatment;</p> </li> <li> <p>contraindications for anticoagulants;</p> </li> <li> <p>life expectancy &lt; 3 months;</p> </li> <li> <p>pregnancy;</p> </li> <li> <p>serum creatinine &gt; 200 µmol/L;</p> </li> <li> <p>platelet count &lt; 100 × 10<sup>9</sup>/L. </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Rembrandt Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>456</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0021"> <li> <p>symptomatic pulmonary embolism;</p> </li> <li> <p>previously documented thrombosis in the same leg, unless complete ultrasound normalisation had been documented; </p> </li> <li> <p>known bleeding tendency;</p> </li> <li> <p>surgery within the previous 5 days;</p> </li> <li> <p>body weight of &lt; 50 kg or &gt; 100 kg;</p> </li> <li> <p>any contraindication for anticoagulant treatment;</p> </li> <li> <p>treatment with therapeutic dosages of anticoagulants for &gt; 24 hours before randomisation;</p> </li> <li> <p>pregnant women, breastfeeding or premenopausal and not using effective contraceptive measures; </p> </li> <li> <p>drug‐addictive disorder or alcoholism;</p> </li> <li> <p>known renal insufficiency;</p> </li> <li> <p>life expectancy of &lt; 6 months;</p> </li> <li> <p>participation in another clinical drug study within the previous 90 days.</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Van Gogh Trial‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2904</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0022"> <li> <p>treatment with a therapeutic dose of LMWH or unfractionated heparin for more than 36 hours before randomisation; </p> </li> <li> <p>treatment with thrombolysis, embolectomy, or a vena cava filter required for the current episode; </p> </li> <li> <p>another indication for a vitamin K antagonist;</p> </li> <li> <p>pregnancy or breastfeeding;</p> </li> <li> <p>creatinine clearance of less than 10 mL per minute;</p> </li> <li> <p>uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg); </p> </li> <li> <p>life expectancy of &lt; 3 months.</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DVT: deep vein thrombosis<br/> LMWH: low molecular weight heparin </p> </div> </div> <div class="table" id="CD011782-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies: Outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary efficacy outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary harm outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time points measured of outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQUINOX</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Idrabiotaparinux: 3.0 mg once a week for 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Idraparinux: 2.5 mg once a week for 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 and 9 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MATISSE‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) fondaparinux: 5.0 mg (weight &lt; 50 kg) or 7.5 mg (50 kg &gt; weight &lt; 100 kg) or 10 mg (weight &gt; 100 kg) once daily for 5 days; </p> <p>(2) vitamin K antagonist started within 72 hours and continued for 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard therapy:</p> <p>(1) enoxaparin: 1 mg/kg twice daily for 5 days;</p> <p>(2) vitamin K antagonist started within 72 hours and continued for 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PERSIST Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 5 to 7 days of LMWH (enoxaparin, 1 mg/kg);</p> <p>(2) idraparinux: 2.5 mg, 5 mg, 7.5 mg, or 10 mg once a week without weight adjustment continued for 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard therapy:</p> <p>(1) 5 to 7 days of enoxaparin (1 mg/kg);</p> <p>(2) warfarin target to an INR rate between 2.0 to 3.0 continued for 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Rembrandt Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) fondaparinux: 5.0 mg, 7.5 mg, or 10 mg once daily without weight adjustment for ± 5 days; </p> <p>(2) vitamin K antagonist started on day 1 or 2 and continued for ± 90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard therapy:</p> <p>(1) dalteparin: 100 IU/kg twice daily for ± 5 days;</p> <p>(2) vitamin K antagonist started on day 1 or 2 and continued for ± 90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Van Gogh Trial‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Idraparinux: 2.5 mg once a week for 3 or 6 months, as assessed by the treating physician</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard therapy:</p> <p>(1) tinzaparin, enoxaparin, or intravenous heparin: dose adjusted for the activated partial thromboplastin time (ratio 1.5 to 2.5); </p> <p>(2) warfarin or acenocoumarol started within 24 hours and target to INR 2.0 to 3.0 for 3 or 6 months, as assessed by the treating physician </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant bleeding and all‐cause mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 or 6 months</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>INR: international normalised ratio<br/> LMWH: low molecular weight heparin </p> </div> </div> <section id="CD011782-sec-0057"> <h5 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h5> <p>Two studies, <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> and <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>, compared fondaparinux plus vitamin K antagonist to standard therapy consisting of LMWH, enoxaparin and dalteparin respectively, and vitamin K antagonists. In both trials, fondaparinux was administered once a day for five days. Vitamin K antagonists were started within 72 hours in both trials, and treatment was continued for 3 months. In both trials, the initial treatment with the intervention medications (fondaparinux or LMWH) was discontinued when the international normalised ratio (INR) was maintained greater than 2.0 for two or more consecutive days. These trials randomised a total of 2658 participants. </p> <p>The <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> study adjusted doses according to body weight: 5.0 mg if weight was less than 50 kg, 7.5 mg if weight was greater than 50 kg but less than 100 kg, or 10 mg if weight was greater than 100 kg. Data on secondary harmful outcomes from this trial were available from the manufacturer's clinical trial register (presented as a summary of the results), and we extracted data on these outcomes from this source. </p> <p>The <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a> randomised participants to one of three doses of fondaparinux without weight adjustment (5.0 mg, 7.5 mg, or 10 mg). </p> <p>The <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> study reported an intention‐to‐treat analysis, but three participants were excluded after randomisation because they did not receive treatment. Additional participants were excluded due to suspected inefficacy and harmful effects, and the report did not explain how outcome data for missing participants were analysed. The <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a> states that no participants were lost to follow‐up. </p> </section> <section id="CD011782-sec-0058"> <h5 class="title">Idrabiotaparinux versus idraparinux</h5> <p>One study compared idrabiotaparinux 3.0 mg once a week with idraparinux 2.5 mg once a week (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>). Both interventions were administered for six months. An additional follow‐up measurement was undertaken three months after the end of treatment and included participants who did not receive avidin (the antidote for idrabiotaparinux) (total follow‐up of nine months). Although the study report refers to an intention‐to‐treat analysis, 88 participants were missing due to withdrawals or lost to follow‐up, and it is unclear how outcome data for missing participants were handled. Contact with the study authors indicated that these data were considered missing ("censored"). The study reports that 741 participants completed the six‐month clinical follow‐up, and 700 participants completed the additional follow‐up. </p> <p>The trial randomised 757 participants. Data regarding the two follow‐up periods were analysed cumulatively and according to the total number of participants randomised. </p> </section> <section id="CD011782-sec-0059"> <h5 class="title">LMWH and idraparinux versus standard therapy</h5> <p>The <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a> investigated the effects of initial treatment with LMWH (enoxaparin) followed by three months of idraparinux compared to standard therapy consisting of an initial treatment with LMWH followed by warfarin. The LMWH (enoxaparin) was administered for five to seven days (1 mg/kg), after which participants were randomised to receive one of four doses of idraparinux (2.5 mg, 5 mg, 7.5 mg, or 10 mg) or warfarin target to an INR rate between 2.0 to 3.0. The doses of idraparinux were administered without weight adjustment. </p> <p>Treatment with idraparinux and warfarin continued for three months. A total of 701 participants were enrolled and received initial treatment with LMWH. Thirty‐five patients were excluded, after which 659 participants were randomised. The trial reports two consent withdrawals, 45 missing data due to lost to follow‐up, and 66 premature discontinuation of treatment. The analysis considered all randomised participants as the denominator, although the study report indicates that efficacy analysis only included participants who received treatment and for whom the primary outcome data were available. </p> </section> <section id="CD011782-sec-0060"> <h5 class="title">Idraparinux versus standard therapy</h5> <p>One trial compared therapy with idraparinux to standard therapy consisting of initial therapy with LMWH (tinzaparin or enoxaparin) or unfractionated heparin followed by warfarin or acenocoumarol (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). The treatment was administered for three or six months depending on the judgement of the treating physician. The intervention group received a dose of 2.5 mg of idraparinux administered once a week. The comparison group received heparin for at least five days, with doses adjusted for the activated partial‐thromboplastin time (ratio: 1.5 to 2.5), and had warfarin or acenocoumarol administered within 24 hours and target to INR 2.0 to 3.0. The majority of the participants in the comparison arm received LMWH as initial treatment (1408, 98.3%), and heparin was discontinued when the INR was 2.0 or more for two consecutive days. </p> <p>The <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a> was designed as two separated RCTs, one in which participants were diagnosed with DVT and the other those diagnosed with pulmonary embolism. The DVT study followed a total of 2904 participants. Based on the judgement of the treating physician, 637 participants had treatment planned for three months (idraparinux: n = 321; standard therapy: n = 316), and the remaining participants received treatment for 6 months (idraparinux: n = 1131; standard therapy: n = 1136). The data analysed comprise 2904 participants receiving treatment for 3 months and 2267 participants receiving treatment for 6 months. We did not use cumulative data for the second follow‐up period since only a proportion of participants entered this part of the study. </p> </section> </section> <section id="CD011782-sec-0061"> <h4 class="title">Excluded studies</h4> <p>We excluded 17 reports referring to six studies. We excluded trials enrolling participants with pulmonary embolism (<a href="./references#CD011782-bbs2-0006" title="BullerHR , GallusAS , PillionG , PrinsMH , RaskobGE , the Cassiopea Investigators. Enoxaparin followed by once‐weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double‐blind, double‐dummy, non‐inferiority trial. Lancet2012;379:123‐9. ">Cassiopea Investigators</a>; <a href="./references#CD011782-bbs2-0008" title="A multicentre, randomized, open‐label study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus adjusted dose intravenous (i.v.) unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE) (MATISSE‐PE). Study No: 63123. GlaxoSmithKline Clinical Trial Register2005. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. New England Journal of Medicine2003;349(18):1695‐702. DavidsonBL , BullerHR , DecoususH , GallusA , GentM , PiovellaF , et al. Outcomes in obese patients of pulmonary embolism (PE) and deep vein thrombosis (DVT) treatment with fondaparinux or (LMW) heparins: the Matisse trials. Journal of Thrombosis and Haemostasis2005;3(Suppl S1):P0424. DavidsonBL , the Matisse Steering Committee and Investigators. Fondaparinux, a pentasaccharide vs unfractionated heparin (UH) or low molecular weight heparin (LMWH) for pulmonary embolism (PE) or deep vein thrombosis (DVT): the Matisse trials [abstract]. American Thoracic Society 99th International Conference. 2003:A119. Matisse Investigators. Fondaparinux (Arixtra) in comparison to (low molecular weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism ‐ the Matisse clinical outcome studies. Blood2002; Vol. 100:Abstract 302. PiovelaF . Initial outpatient treatment of pulmonary embolism with fondaparinux (Arixtra): the Matisse‐Pe trial. Hematology Journal2004;Suppl 2:53. The Matisse Investigators. The MATISSE‐PE trial, a multicenter, randomized, open study comparing once‐daily fondaparinux (Arixtra®) with adjusted‐dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism. Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract number OC331. ">MATISSE‐PE</a>), including narrative reviews summarising the results of the DVT study and the pulmonary embolism study of the <a href="./references#CD011782-bbs2-0008" title="A multicentre, randomized, open‐label study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus adjusted dose intravenous (i.v.) unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE) (MATISSE‐PE). Study No: 63123. GlaxoSmithKline Clinical Trial Register2005. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. New England Journal of Medicine2003;349(18):1695‐702. DavidsonBL , BullerHR , DecoususH , GallusA , GentM , PiovellaF , et al. Outcomes in obese patients of pulmonary embolism (PE) and deep vein thrombosis (DVT) treatment with fondaparinux or (LMW) heparins: the Matisse trials. Journal of Thrombosis and Haemostasis2005;3(Suppl S1):P0424. DavidsonBL , the Matisse Steering Committee and Investigators. Fondaparinux, a pentasaccharide vs unfractionated heparin (UH) or low molecular weight heparin (LMWH) for pulmonary embolism (PE) or deep vein thrombosis (DVT): the Matisse trials [abstract]. American Thoracic Society 99th International Conference. 2003:A119. Matisse Investigators. Fondaparinux (Arixtra) in comparison to (low molecular weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism ‐ the Matisse clinical outcome studies. Blood2002; Vol. 100:Abstract 302. PiovelaF . Initial outpatient treatment of pulmonary embolism with fondaparinux (Arixtra): the Matisse‐Pe trial. Hematology Journal2004;Suppl 2:53. The Matisse Investigators. The MATISSE‐PE trial, a multicenter, randomized, open study comparing once‐daily fondaparinux (Arixtra®) with adjusted‐dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism. Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract number OC331. ">MATISSE‐PE</a> trial; and trials investigating pentasaccharides for extended prophylaxis of DVT (<a href="./references#CD011782-bbs2-0010" title="BullerHR . Once weekly subcutaneous idraparinux versus placebo in the extended treatment of deep‐vein thrombosis or pulmonary embolism. The Van Gogh Investigators. Blood2006; Vol. 108, issue 11 Pt 1:172. BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006; Vol. 108, issue 11:6‐7. HarenbergJ , JorgI , VukojevicY , MikusG , WeissC . Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. European Journal of Clinical Pharmacology2008;64(6):555‐63. The Van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. New England Journal of Medicine2007;357(11):1105‐12. ">The Van Gogh Extension</a>). One study was interested in the potential of avidin to reverse the anti‐factor Xa activity of idrabiotaparinux and in the bioequipotency of idrabiotaparinux and idraparinux (<a href="./references#CD011782-bbs2-0007" title="PatyI , TrelluM , DestorsJM , CortezP , BoelleE , SanderinkG . Reversibility of the anti‐FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. Journal of Thrombosis and Haemostasis2010;8(4):722‐9. TrelluM , FauJ‐B , CortezP , ChengS , PatyI , BoelleE , et al. Bioequipotency of idraparinux and idrabiotaparinux after once weekly dosing in healthy volunteers and patients treated for acute deep vein thrombosis. British Journal of Clinical Pharmacology2013;75(5):1255‐64. ">EQUINOXa</a>). One trial did not diagnose DVT in accordance with standard methods (<a href="./references#CD011782-bbs2-0009" title="NakamuraM , OkanoY , MinamigichiH , TsujimotoH , NakajimaH , KuniedaT . Clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Chest2010; Vol. 138, issue 4. NakamuraMO . Multidetector‐row computed tomography‐based clinical assessment of fondaparinux for treatment of acute pulmonary embolism and acute deep vein thrombosis in Japanese patients. Circulation Journal2011;75(6):1424‐32. ">Nakamura 2011</a>), and one potentially relevant study did not include a control group (<a href="./references#CD011782-bbs2-0011" title="YoungG , YeeDL , O'BrienSH , KhannaR , BarbourA , NugentDJ . FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatric Blood and Cancer2011;57(6):1049‐54. ">Young 2011</a>). </p> </section> </section> <section id="CD011782-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed risk of bias in individual studies using Cochrane's 'Risk of bias' tool (<a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Three domains were assessed taking into consideration different groups (participants and personnel) or outcomes (efficacy and harm outcomes). Summaries of the 'Risk of bias' assessment are shown in <a href="#CD011782-fig-0002">Figure 2</a> and <a href="#CD011782-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011782-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011782-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011782-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011782-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011782-sec-0063"> <h4 class="title">Allocation</h4> <p>We considered random sequence generation as at low risk of bias in most of the included studies (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>; <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). One study was reported as randomised but no information on the methods to achieve an adequate randomisation was provided, therefore the random sequence generation was judged as unclear for this trial (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). </p> <p>We deemed allocation concealment as at low risk of bias in three studies (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). Two studies failed to report methods to guarantee allocation concealment and were judged as at unclear risk of bias in this domain (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). </p> </section> <section id="CD011782-sec-0064"> <h4 class="title">Blinding</h4> <p>We assessed blinding (performance bias) separately for participants and personnel in order to better judge the risk of bias of studies reporting complete and incomplete methods applied to ensure blinding of both participants and personnel. </p> <p>We considered blinding of participants as low risk in three studies (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). One study blinded participants to different doses administered of the intervention, but the type of drug of the treatment groups was open, therefore we considered this study as at high risk of bias (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). We judged one trial that was reported as open label as at high risk of bias (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> <p>We judged blinding of personnel as at low risk of bias in two studies (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). In one study, the different doses administered of the intervention were blinded, but the type of drug of the treatment groups was open to the investigators (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). We deemed this study as at high risk of bias (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). One study did not report measures to blind personnel and was judged as at unclear risk of bias with regard to blinding of personnel (<a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). We judged one trial that was reported as open label as at high risk of bias (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> <p>We determined blinding of outcome assessment (detection bias) separately for efficacy and harm outcomes. We assessed all the included studies as at low risk of bias regarding blinding of efficacy outcome assessment, but only one study was at low risk of bias for blinding of harm outcome assessment (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). We judged the remaining four studies as at high risk of bias: </p> <p> <ul id="CD011782-list-0023"> <li> <p>in the <a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a> and <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> trials, the efficacy outcomes were classified by an independent central adjudication committee whose members were unaware of treatment assignment, however of the harmful effects, only bleeding was reported as being diagnosed by a committee unaware of treatment assignment; </p> </li> <li> <p>in the <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial,</a> a central adjudication committee, blinded to treatment allocation, reviewed the diagnosis of the efficacy outcomes, however harmful outcomes were monitored by a committee only partially blinded to treatment groups; </p> </li> <li> <p>in the <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>, efficacy outcomes were interpreted by a central committee unaware of treatment allocation. No information was provided on how data of harmful outcomes were collected, interpreted, or diagnosed. </p> </li> </ul> </p> </section> <section id="CD011782-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed incomplete outcome data (attrition bias) separately for primary efficacy and harm outcomes. We chose this methodological option to account for differences in the methods relating specifically to these types of outcomes. </p> <p>We judged one study, <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>, as at low risk of bias for incomplete outcome data of efficacy outcomes and three studies as at high risk of bias (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). The <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a> excluded participants after randomisation and also reported treatment discontinuation due to suspected inefficacy and harmful effects. The <a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a> trial reported reasons for withdrawals and loss to follow‐up related to efficacy, prognosis, and adverse effects. The <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a> reported a relevant number of participants (113/659) as lost to follow‐up or discontinued prematurely after randomisation with reasons potentially related to prognosis. The efficacy analysis is also described as including only participants who received treatment and for whom the primary outcome was available. </p> <p>We judged risk of bias for incomplete outcome data of the primary efficacy outcome as unclear in one study since reasons for withdrawals and loss to follow‐up were not clearly detailed, and there was no explanation for how outcome data for 15 missing participants were handled (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). </p> <p>We judged one study as at low risk of bias for incomplete outcome data of harm outcomes (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). We considered all the remaining trials as at high risk of bias (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>; <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>): </p> <p> <ul id="CD011782-list-0024"> <li> <p>in the <a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a> trial, the main harmful effects were reported (bleeding and death), but other harmful effects were reported only if incidence was higher than 2%; </p> </li> <li> <p>in the <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>, a relevant number of participants withdrew enrolment in the studies due to harm outcomes. Moreover, definitions and descriptions of other harm outcomes besides bleeding were missing; </p> </li> <li> <p>in the <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>, only major bleeding was reported; </p> </li> <li> <p>the <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a> reported harm outcomes among the reasons for treatment discontinuation, and only adverse effects with incidence higher than 1% were detailed. </p> </li> </ul> </p> <p>We contacted authors seeking additional information regarding incomplete outcome data. However, it was explained to us that data needed to be sought from the pharmaceutical company that sponsored the trials. Unfortunately, we lacked resources to seek and analyse data from this type of non‐published source for this version of the review. </p> </section> <section id="CD011782-sec-0066"> <h4 class="title">Selective reporting</h4> <p>We considered selective reporting (reporting bias) as at low risk of bias in two studies (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). We judged the remaining four studies as at unclear risk of bias (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>), as: </p> <p> <ul id="CD011782-list-0025"> <li> <p>results about bleeding were included in the trial report (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>), but results on additional harmful effects were presented only in a summary report of the results available in the clinical study register of the manufacturer of fondaparinux. We were unsure whether or not this would critically impact the validity of the study's results; </p> </li> <li> <p>we could not identify the study trial protocol and were therefore unable to judge selective reporting bias (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). </p> </li> </ul> </p> </section> <section id="CD011782-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>All included studies disclosed that the investigators responsible for the study or members of the executive committee acted as advisors or employees of the pharmaceutical company that sponsored the trials. We therefore deemed the studies as at high risk of bias related to conflicts of interest. </p> </section> </section> <section id="CD011782-sec-0068"> <h3 class="title" id="CD011782-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD011782-tbl-0001"><b>Summary of findings for the main comparison</b> Fondaparinux plus vitamin K antagonist compared to standard therapy for the treatment of deep vein thrombosis</a>; <a href="./full#CD011782-tbl-0002"><b>Summary of findings 2</b> Idrabiotaparinux compared to idraparinux for the treatment of deep vein thrombosis</a>; <a href="./full#CD011782-tbl-0003"><b>Summary of findings 3</b> Low molecular weight heparin and idraparinux compared to standard therapy for the treatment of deep vein thrombosis</a>; <a href="./full#CD011782-tbl-0004"><b>Summary of findings 4</b> Idraparinux compared to standard therapy for the treatment of deep vein thrombosis</a> </p> <p>The main findings of the review results are described in <a href="./full#CD011782-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011782-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011782-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011782-tbl-0004">summary of findings Table 4</a>. </p> <p>We grouped included studies according to comparisons of anticoagulant therapies:</p> <p> <ul id="CD011782-list-0026"> <li> <p>fondaparinux plus vitamin K antagonist versus standard therapy;</p> </li> <li> <p>idrabiotaparinux versus idraparinux;</p> </li> <li> <p>LMWH and idraparinux versus standard therapy;</p> </li> <li> <p>idraparinux versus standard therapy.</p> </li> </ul> </p> <p>In our protocol, we planned to assess our primary efficacy outcome, recurrent venous thromboembolism (VTE), during a six‐month study period. However, only two studies followed participants for six months (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). The remaining studies assessed the outcomes at three months' follow‐up. We therefore analysed data according to the time points measured in the included trials. </p> <p>We planned to assess reporting bias using a funnel plot, but the insufficient number of studies included in each analysis did not provide appropriate visual inspection for asymmetry on the scatter plot, and therefore the funnel plot was not used. </p> <section id="CD011782-sec-0069"> <h4 class="title">Primary efficacy outcome: any VTE</h4> <section id="CD011782-sec-0070"> <h5 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h5> <p>There was no clear difference in the risk of recurrent VTE at three months' follow‐up comparing participants treated with fondaparinux plus vitamin K antagonist and those treated with standard therapy (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.43 to 1.47; <a href="./references#CD011782-fig-0008" title="">Analysis 1.1</a>; <a href="#CD011782-fig-0004">Figure 4</a>); moderate‐quality evidence. The results were consistent across studies and independent of the risk of bias of the individual studies. Heterogeneity was detected at 35% (P = 0.21) as assessed by the I<sup>2</sup> statistic. </p> <div class="figure" id="CD011782-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.1 Recurrent VTE at 3 months' follow‐up." data-id="CD011782-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.1 Recurrent VTE at 3 months' follow‐up. </p> </div> </div> </div> <p>Two studies (n = 2658) contributed data to this analysis (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). Data were only extracted from the study reports. </p> </section> <section id="CD011782-sec-0071"> <h5 class="title">Idrabiotaparinux versus idraparinux</h5> <p>There was no clear difference in the risk of recurrent VTE at six months' follow‐up between idrabiotaparinux and idraparinux (RR 0.72, 95% CI 0.31 to 1.69; <a href="./references#CD011782-fig-0028" title="">Analysis 2.1</a>); low‐quality evidence. </p> <p>At nine months' follow‐up, the estimated risk of VTE again did not show a clear difference between intervention groups (RR 0.60, 95% CI 0.28 to 1.31; <a href="./references#CD011782-fig-0029" title="">Analysis 2.2</a>). </p> <p>One study contributed data to this analysis (n = 757) (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>). </p> </section> <section id="CD011782-sec-0072"> <h5 class="title">LMWH and idraparinux versus standard therapy</h5> <p>The <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a> compared the effects of an initial treatment with LMWH followed by three months of idraparinux (2.5 mg, 5 mg, 7.5 mg, or 10 mg) versus standard therapy. The trial reports performed an analysis considering as denominator randomised participants who received randomised treatment (n = 659), not considering in the analysis two participants who withdrew consent after randomisation. Primary outcome data were available for only 614 participants, the authors acknowledging a significant amount of missing data due to exclusions, withdrawals, and loss to follow‐up. However, details were not provided according to treatment groups. We analysed data as available accounting for a high risk of bias in this analysis, which was reflected in the quality of evidence evaluated in the 'Summary of findings' table. Since we do not know the amount of missing data according to the allocated treatment, we could not evaluate the possible direction of the bias. </p> <p>No events of recurrent VTE were reported in the groups of participants receiving LMWH followed by idraparinux 2.5 mg, 5 mg, or 7.5 mg. Three events of recurrent VTE occurred in participants receiving 10.0 mg of idraparinux, and two events were reported in the group receiving standard therapy. However, two participants receiving 2.5 mg of idraparinux and one receiving 5.0 mg of idraparinux discontinued treatment due to a suspected VTE. Two participants in the standard therapy group were also excluded due to a suspected VTE. Comparing the cases considered as confirmed by the trialists, and excluding the groups with zero outcomes reported, we were able to compare quantitatively the risk of VTE of LMWH followed by 10.0 mg of idraparinux with standard therapy. This analysis did not demonstrate a clear difference in the risk of recurrent VTE comparing these two treatment groups (RR 1.51, 95% CI 0.26 to 8.90; <a href="./references#CD011782-fig-0042" title="">Analysis 3.1</a>); very low‐quality evidence. </p> </section> <section id="CD011782-sec-0073"> <h5 class="title">Idraparinux versus standard therapy</h5> <p>There was no evidence of a difference in the risk of recurrent VTE at three months' follow‐up when idraparinux was compared to standard therapy (RR 0.98, 95% CI 0.64 to 1.48; <a href="./references#CD011782-fig-0050" title="">Analysis 4.1</a>); low‐quality evidence. We found what appeared to be a similar result in people receiving treatment for six months (RR 1.00, 95% CI 0.66 to 1.53; <a href="./references#CD011782-fig-0051" title="">Analysis 4.2</a>). Only one study contributed data for this analysis (n = 2904 and n = 2267, at three and six months' follow‐up, respectively) (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> </section> </section> <section id="CD011782-sec-0074"> <h4 class="title">Primary harm outcome: major and clinically relevant bleeding</h4> <section id="CD011782-sec-0075"> <h5 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h5> <p>Events of bleeding were analysed during the initial treatment period with fondaparinux (approximately five days), and for the entire study (three months). </p> <section id="CD011782-sec-0076"> <h6 class="title">Initial period of treatment (approximately five days)</h6> <p>Major and clinically relevant bleeding occurred in 63 of 1425 participants treated with fondaparinux plus vitamin K antagonist (AR 4.42%, 95% CI 3.47 to 5.62) and in 59 of 1220 participants receiving treatment with standard therapy (AR 4.84%, 95% CI 3.77 to 6.19). There was no clear difference in bleeding between intervention groups (RR 0.80, 95% CI 0.56 to 1.13; <a href="./references#CD011782-fig-0009" title="">Analysis 1.2</a>; <a href="#CD011782-fig-0005">Figure 5</a>). Heterogeneity was not significant in this pooled analysis (I<sup>2</sup> = 0%, P = 0.40). The total number of participants included in this analysis was 2645 (considering the safety population defined by the trials as all participants receiving at least one injection of the study treatment in both trials contributing data, <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> and <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). </p> <div class="figure" id="CD011782-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.2 Bleeding [initial treatment]." data-id="CD011782-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.2 Bleeding [initial treatment]. </p> </div> </div> </div> <p>Participants receiving fondaparinux presented an absolute risk of major bleeding equal to 1.26% (95% CI 0.80 to 1.99) (18 out of 1425 participants), and this risk was equal to 1.07% (95% CI 0.62 to 1.82) (13 out of 1220 participants) in participants receiving standard therapy. There was no clear difference in major bleeding between the two interventions (RR 1.15, 95% CI 0.39 to 3.44; <a href="./references#CD011782-fig-0010" title="">Analysis 1.3</a>; <a href="#CD011782-fig-0006">Figure 6</a>); moderate‐quality evidence. Heterogeneity was estimated as equal to 15% in this pooled analysis by the I<sup>2</sup> statistic (P = 0.28). Two studies contributed data to this analysis (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). The total number of participants included in the analysis was 2645. </p> <div class="figure" id="CD011782-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.3 Major bleeding [initial treatment]." data-id="CD011782-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.3 Major bleeding [initial treatment]. </p> </div> </div> </div> <p>Separate data were reported for clinically relevant bleeding in one trial (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). The absolute risk of clinically relevant bleeding was estimated as equal to 2.57% (95% CI 1.78 to 3.68) (28 out of 1091 participants) in the fondaparinux plus vitamin K antagonist group and as equal to 2.30% (95% CI 2.36 to 4.59) (33 out of 1101 participants) in the standard therapy group. There was no clear difference in risk of clinically relevant bleeding (RR 0.86, 95% CI 0.52 to 1.41; <a href="./references#CD011782-fig-0011" title="">Analysis 1.4</a>). The total number of participants included in the analysis was 2192 (data reported only in <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). </p> </section> <section id="CD011782-sec-0077"> <h6 class="title">Three months' follow‐up</h6> <p>Bleeding was a very common outcome at three months' follow‐up in <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> and <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a> (n = 2645). </p> <p>At three months' follow‐up in the <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> and <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>s (n = 2645), the incidence of bleeding in the fondaparinux arm was as high as 8.56% (95% CI 7.22 to 10.13) (122 out of 1425 participants), and in the standard therapy group it was similarly high and equal to 8.93% (95% CI 7.46 to 10.67) (109 out of 1220 participants). There was no clear difference in bleeding between groups (RR 0.81, 95% CI 0.50 to 1.32) (<a href="./references#CD011782-fig-0012" title="">Analysis 1.5</a>). Heterogeneity was moderate and estimated as equal to 65% in this pooled analysis by the I<sup>2</sup> statistic (P = 0.09). </p> <p>Major bleeding occurred in 35 of 1425 participants receiving fondaparinux plus vitamin K antagonist (AR 2.46%, 95% CI 1.77 to 3.40) and in 29 of 1220 participants receiving standard therapy (AR 2.38%, 95% CI 1.66 to 3.39). The risk of major bleeding was similar between treatments (RR 1.05, 95% CI 0.64 to 1.71; <a href="./references#CD011782-fig-0013" title="">Analysis 1.6</a>); moderate‐quality evidence. Heterogeneity was estimated as equal to 0% in this pooled analysis by the I<sup>2</sup> statistic (P = 0.71). </p> <p>One trial reported clinically relevant bleeding at three months' follow‐up (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). The absolute risk of clinically relevant bleeding was equal to 5.50% (95% CI 4.30 to 7.02) (60 out of 1091 participants) in the fondaparinux plus vitamin K antagonist group and 5.72% (95% CI 4.50 to 7.25) (63 out of 1101 participants) in the standard therapy group. The risk of clinically relevant bleeding was similar between treatment arms (RR 0.96, 95% CI 0.68 to 1.36; <a href="./references#CD011782-fig-0014" title="">Analysis 1.7</a>). The total number of participants included in the analysis was 2192 (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). </p> </section> </section> <section id="CD011782-sec-0078"> <h5 class="title">Idrabiotaparinux versus idraparinux</h5> <section id="CD011782-sec-0079"> <h6 class="title">Six months' follow‐up</h6> <p>Major and clinically relevant bleeding occurred in a total of 23 of the 385 participants receiving idrabiotaparinux (AR 5.97%, 95% CI 4.01 to 8.80) and in 41 of 370 participants receiving idraparinux (AR 11.08%, 95% CI 8.27 to 14.69). The risk of bleeding was higher in participants receiving idrabiotaparinux (RR 0.54, 95% CI 0.33 to 0.88; <a href="./references#CD011782-fig-0030" title="">Analysis 2.3</a>). </p> <p>Major bleeding occurred in 3 out of 385 participants receiving idrabiotaparinux (AR 0.78%, 95% CI 0.26 to 2.27) and in 14 of 370 participants receiving idraparinux (AR 3.78%, 95% CI 2.27 to 6.25). The risk of major bleeding appeared to be lower in participants receiving idrabiotaparinux in comparison with participants treated with idraparinux (RR 0.21, 95% CI 0.06 to 0.71; <a href="./references#CD011782-fig-0031" title="">Analysis 2.4</a>); low‐quality evidence. </p> <p>Clinically relevant bleeding occurred with incidences of 5.19% (95% CI 3.39 to 7.89) (20 out of 385 participants) in participants receiving idrabiotaparinux, and of 7.30% (95% CI 5.06 to 10.41) (27 out of 370 participants) in participants receiving idraparinux. There was no clear difference in bleeding between intervention groups (RR 0.71, 95% CI 0.41 to 1.25; <a href="./references#CD011782-fig-0032" title="">Analysis 2.5</a>). </p> <p>One study provided data for these analyses (n = 755 participants; safety population defined as all patients receiving at least one injection of the study treatment) (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>). </p> </section> <section id="CD011782-sec-0080"> <h6 class="title">Nine months' follow‐up</h6> <p>Major and clinically relevant bleeding occurred in 32 of 385 participants receiving idrabiotaparinux (AR 8.31%, 95% CI 5.95 to 11.5) and in 52 of 370 participants receiving idraparinux (AR 14.05%, 95% CI 10.88 to 17.97). The risk of bleeding at nine months was higher in participants receiving idrabiotaparinux (RR 0.59, 95% CI 0.39 to 90; <a href="./references#CD011782-fig-0033" title="">Analysis 2.6</a>). </p> <p>Major bleeding occurred in 5 of 385 participants in the idrabiotaparinux group (AR 1.30%, 95% CI 0.56 to 3.00) and in 17 of 370 participants in the idraparinux group (AR 4.60%, 95% CI 2.89 to 7.23). The risk of major bleeding was higher in participants treated with idrabiotaparinux (RR 0.28, 95% CI 0.11 to 0.76; <a href="./references#CD011782-fig-0034" title="">Analysis 2.7</a>). </p> <p>Clinically relevant bleeding occurred in 27 out of 385 participants receiving idrabiotaparinux (AR 7.01%, 95% CI 4.86 to 10.01) and in 35 out of 370 participants receiving idraparinux (AR 9.46%, CI 95% 6.88 to 12.87). Relative analysis did not demonstrate a clear difference in the risk of major bleeding between intervention groups (RR 0.74, 95% CI 0.46 to 1.20; <a href="./references#CD011782-fig-0035" title="">Analysis 2.8</a>). </p> <p>Data for these analysis were extracted from one study (n = 755 participants; safety population defined as all patients receiving at least one injection of the study treatment) (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>). </p> </section> </section> <section id="CD011782-sec-0081"> <h5 class="title">LMWH and idraparinux versus standard therapy</h5> <p>Bleeding was reported as a reason for discontinuation of treatment in 17 participants receiving idraparinux after LMWH (all doses combined). We took into consideration the exclusion of participants based on prognosis in the 'Risk of bias' assessment and in the evaluation of the quality of the body of the evidence in the 'Summary of findings' table. </p> <p>The total number of participants contributing data to these analyses was 659 (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). Bleeding was reported at three months. No data were available after five days of initial treatment. </p> <p>Major and other clinically relevant bleeding occurred in participants receiving LMWH followed by idraparinux, especially in higher doses. Absolute frequencies were: </p> <p> <ul id="CD011782-list-0027"> <li> <p>LMWH + idraparinux 2.5 mg (3/131): 2.29% (95% CI 0.78 to 6.52);</p> </li> <li> <p>LMWH + idraparinux 5.0 mg (16/135): 11.85% (95% CI 7.43 to 18.39);</p> </li> <li> <p>LMWH + idraparinux 7.5 mg (18/130): 13.85% (95% CI 8.94 to 20.83);</p> </li> <li> <p>LMWH + idraparinux 10.0 mg (20/131): 15.27% (95% CI 10.11 to 22.41).</p> </li> </ul> </p> <p>The RRs of bleeding for the various doses of idraparinux in comparison with standard therapy were: </p> <p> <ul id="CD011782-list-0028"> <li> <p>LMWH + idraparinux 2.5 mg: 0.27 (95% CI 0.08 to 0.96; <a href="./references#CD011782-fig-0043" title="">Analysis 3.2</a>); </p> </li> <li> <p>LMWH + idraparinux 5.0 mg: 1.42 (95% CI 0.69 to 2.95; <a href="./references#CD011782-fig-0044" title="">Analysis 3.3</a>); </p> </li> <li> <p>LMWH + idraparinux 7.5 mg: 1.66 (95% CI 0.82 to 3.38; <a href="./references#CD011782-fig-0045" title="">Analysis 3.4</a>); </p> </li> <li> <p>LMWH + idraparinux 10.0 mg: 1.83 (95% CI 0.91 to 3.67; <a href="./references#CD011782-fig-0046" title="">Analysis 3.5</a>). </p> </li> </ul> </p> <p>Combining participants receiving LMWH and any dose of idraparinux, 57 out of 527 participants had a major or other clinically relevant bleeding event (10.82%, 95% CI 8.44 to 13.76). In comparison, of the 132 participants treated with standard therapy, 11 had a major or other clinically relevant bleeding event (8.33, 95% CI 4.72 to 14.31). Overall, there was no clear difference in major and other clinically relevant bleeding between treatment groups (RR 1.30, 95% CI 0.70 to 2.40; <a href="./references#CD011782-fig-0047" title="">Analysis 3.6</a>). </p> <p>Major bleeding occurred in 4, 2, and 9 of the participants receiving 5.0 mg, 7.5 mg, and 10.0 mg of idraparinux, respectively. No major bleeding was reported in participants treated with 2.5 mg of idraparinux. Absolute frequencies were: </p> <p> <ul id="CD011782-list-0029"> <li> <p>LMWH + idraparinux 5.0 mg (4/135): 2.96% (95% CI 1.16 to 7.37);</p> </li> <li> <p>LMWH + idraparinux 7.5 mg (2/130): 1.54% (95% CI 0.42 to 5.44);</p> </li> <li> <p>LMWH + idraparinux 10.0 mg (9/131): 6.87% (95% CI 3.66 to 12.54).</p> </li> </ul> </p> <p>One event of major bleeding occurred in participants allocated to receive standard therapy (1/132; 0.76%, 95% CI 0.14 to 4.16). </p> <p>When participants receiving LMWH and any dose of idraparinux were combined, there was no clear difference in major bleeding between the idraparinux group and the standard therapy group (RR 3.76, 95% CI 0.50 to 28.18; <a href="./references#CD011782-fig-0048" title="">Analysis 3.7</a>); very low‐quality evidence. </p> <p>Clinically relevant bleeding was not reported separately.</p> </section> <section id="CD011782-sec-0082"> <h5 class="title">Idraparinux versus standard therapy</h5> <p>Only one study contributed data to this analysis (n = 2904 and n = 2267, three and six months' follow‐up, respectively) (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> <section id="CD011782-sec-0083"> <h6 class="title">Three months' follow‐up</h6> <p>Major and clinically relevant bleeding occurred in 65 participants receiving idraparinux, a frequency of bleeding of 4.48% (95% CI 3.53 to 5.67). A total of 101 participants receiving standard therapy had major and clinically relevant bleeding, a frequency of 6.96% (95% CI 5.76 to 8.38). Participants receiving idraparinux appeared to be at a reduced risk of bleeding in comparison to standard therapy (RR 0.64, 95% CI 0.48 to 0.87; <a href="./references#CD011782-fig-0052" title="">Analysis 4.3</a>). </p> <p>The reduced frequency of bleeding in the idraparinux group was more significant in the number of events of clinically relevant bleeding: </p> <p> <ul id="CD011782-list-0030"> <li> <p>major bleeding showed no clear difference when comparing the idraparinux group with standard therapy (RR 0.71, 95% CI 0.34 to 1.47; <a href="./references#CD011782-fig-0053" title="">Analysis 4.4</a>); very low‐quality evidence; </p> </li> <li> <p>clinically relevant bleeding was slightly reduced in the idraparinux group compared with the standard therapy group (RR 0.63, 95% CI 0.45 to 0.88; <a href="./references#CD011782-fig-0054" title="">Analysis 4.5</a>). </p> </li> </ul> </p> </section> <section id="CD011782-sec-0084"> <h6 class="title">Six months' follow‐up</h6> <p>Major and clinically relevant bleeding were a common harmful event in both groups. Major and clinically relevant bleeding occurred in 94 participants receiving idraparinux, a frequency equal to 8.31% (95% CI 6.84 to 10.06). There were 92 events of major and clinically relevant bleeding in participants receiving standard therapy, a frequency equal to 8.10% (95% CI 6.65 to 9.83). The risk of bleeding appears to be similar in people receiving idraparinux in comparison to standard therapy (RR 1.03, 95% CI 0.78 to 1.35; <a href="./references#CD011782-fig-0055" title="">Analysis 4.6</a>). </p> <p>These results were consistent among events of major and clinically relevant bleeding. The RR for major bleeding comparing idraparinux with standard therapy was 1.24, 95% CI 0.66 to 2.34 (<a href="./references#CD011782-fig-0056" title="">Analysis 4.7</a>), and the RR for clinically relevant bleeding comparing idraparinux with standard therapy was 0.98, 95% CI 0.72 to 1.34 (<a href="./references#CD011782-fig-0057" title="">Analysis 4.8</a>). </p> </section> </section> </section> <section id="CD011782-sec-0085"> <h4 class="title">Secondary efficacy outcomes</h4> <section id="CD011782-sec-0086"> <h5 class="title">All‐cause mortality</h5> <section id="CD011782-sec-0087"> <h6 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h6> <p>All‐cause mortality at three months' follow‐up was similar in participants treated with fondaparinux and vitamin K antagonist in comparison with participants receiving standard therapy (RR 0.93, 95% CI 0.45 to 1.91; <a href="./references#CD011782-fig-0015" title="">Analysis 1.8</a>); moderate‐quality evidence. The estimated heterogeneity was significant in this pooled analysis (I<sup>2</sup> = 61%, P = 0.11). Two studies contributed data to this analysis (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). The total number of participants analysed was 2658. </p> </section> <section id="CD011782-sec-0088"> <h6 class="title">Idrabiotaparinux versus idraparinux</h6> <p>There was no clear difference in all‐cause mortality in participants treated with idrabiotaparinux in comparison with participants receiving idraparinux at six months' follow‐up: RR 0.48 (95% CI 0.18 to 1.27; <a href="./references#CD011782-fig-0036" title="">Analysis 2.9</a>); low‐quality evidence. We found similar results at nine months' follow‐up (RR 0.59, 95% CI 0.28 to 1.23; <a href="./references#CD011782-fig-0037" title="">Analysis 2.10</a>). </p> <p>These analyses were based on one trial and data on 757 participants (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>). </p> </section> <section id="CD011782-sec-0089"> <h6 class="title">LMWH and idraparinux versus standard therapy</h6> <p>A total of seven fatal cases were reported in the group receiving idraparinux after LMWH (7/527; AR 1.33%, 95% CI 0.64 to 2.72), and no events in the group receiving standard therapy. </p> <p>We could not estimate the risk of all‐cause mortality due to the low number of cases.</p> <p>This analysis was based on one trial with 659 randomised participants (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). </p> </section> <section id="CD011782-sec-0090"> <h6 class="title">Idraparinux versus standard therapy</h6> <p>There was no clear difference in the risk of all‐cause mortality between participants treated with idraparinux in comparison with those treated with standard therapy, regardless of the follow‐up duration: </p> <p> <ul id="CD011782-list-0031"> <li> <p>three months' follow‐up: RR 1.14 (95% CI 0.69 to 1.86; <a href="./references#CD011782-fig-0058" title="">Analysis 4.9</a>); low‐quality evidence; </p> </li> <li> <p>six months' follow‐up: RR 1.26 (95% CI 0.85 to 1.85; <a href="./references#CD011782-fig-0059" title="">Analysis 4.10</a>). </p> </li> </ul> </p> <p>These analyses were based on one trial involving 2904 randomised participants followed for three months, and 2267 randomised participants followed for six months (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> </section> </section> <section id="CD011782-sec-0091"> <h5 class="title">Recurrent DVT</h5> <section id="CD011782-sec-0092"> <h6 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h6> <p>Only one study included in this comparison reported recurrent DVT at three months' follow‐up (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). Data from 2205 participants did not demonstrate a clear difference in the risk of recurrent DVT between intervention groups (RR 0.65, 95% CI 0.36 to 1.16; <a href="./references#CD011782-fig-0016" title="">Analysis 1.9</a>). </p> </section> <section id="CD011782-sec-0093"> <h6 class="title">Idrabiotaparinux versus idraparinux</h6> <p>There was no clear difference in the risk of recurrent DVT between intervention groups at six months' follow‐up (RR 0.58, 95% CI 0.14 to 2.40; <a href="./references#CD011782-fig-0038" title="">Analysis 2.11</a>). Data on these outcomes were not reported at nine months' follow‐up. </p> <p>This analysis was based on one trial and data on 757 participants (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>). </p> </section> <section id="CD011782-sec-0094"> <h6 class="title">LMWH and idraparinux versus standard therapy</h6> <p>The <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a> (659 randomised participants) reported one event of recurrent DVT in participants receiving 10.0 mg of idraparinux and another one in participants receiving standard therapy. We could not estimate the risk of recurrent DVT due to the low number of cases. </p> </section> <section id="CD011782-sec-0095"> <h6 class="title">Idraparinux versus standard therapy</h6> <p>There was no clear difference in the risk of recurrent DVT between participants treated with idraparinux in comparison with those receiving standard therapy, regardless of the follow‐up duration: </p> <p> <ul id="CD011782-list-0032"> <li> <p>three months' follow‐up: RR 0.94 (95% CI 0.49 to 1.83; <a href="./references#CD011782-fig-0060" title="">Analysis 4.11</a>); </p> </li> <li> <p>six months' follow‐up: RR 1.00 (95% CI 0.53 to 1.92; <a href="./references#CD011782-fig-0061" title="">Analysis 4.12</a>). </p> </li> </ul> </p> <p>These analyses were based on one trial involving 2904 randomised participants followed for three months, and 2267 randomised participants followed for six months (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> </section> </section> <section id="CD011782-sec-0096"> <h5 class="title">Pulmonary embolism</h5> <section id="CD011782-sec-0097"> <h6 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h6> <p>There was no clear difference in the risk of pulmonary embolism at three months' follow‐up comparing treatment with fondaparinux plus vitamin K antagonist versus standard therapy (RR 0.88, 95% CI 0.23 to 3.39; <a href="./references#CD011782-fig-0017" title="">Analysis 1.10</a>). Heterogeneity was evident in this pooled analysis (I<sup>2</sup> = 63%, P = 0.10). Two studies evaluated this outcome and contributed data to this comparison (n = 2658) (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). </p> </section> <section id="CD011782-sec-0098"> <h6 class="title">Idrabiotaparinux versus idraparinux</h6> <p>There was no clear difference in the risk of pulmonary embolism between intervention groups at six months' follow‐up (RR 0.82, 95% CI 0.28 to 2.43; <a href="./references#CD011782-fig-0039" title="">Analysis 2.12</a>). Data on this outcome were not reported at nine months' follow‐up. </p> <p>This analysis was based on one trial and data on 757 participants (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>). </p> </section> <section id="CD011782-sec-0099"> <h6 class="title">LMWH and idraparinux versus standard therapy</h6> <p>The <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a> (659 participants) reported two events of pulmonary embolism in participants receiving 10.0 mg of idraparinux. We could not estimate the risk of pulmonary embolism due to the low number of cases. </p> </section> <section id="CD011782-sec-0100"> <h6 class="title">Idraparinux versus standard therapy</h6> <p>There was no clear difference in the risk of recurrent pulmonary embolism between participants treated with idraparinux in comparison with those receiving standard therapy, regardless of the follow‐up duration: </p> <p> <ul id="CD011782-list-0033"> <li> <p>three months' follow‐up: RR 0.63 (95% CI 0.38 to 1.02; <a href="./references#CD011782-fig-0062" title="">Analysis 4.13</a>); </p> </li> <li> <p>six months' follow‐up: RR 1.00 (95% CI 0.57 to 1.76; <a href="./references#CD011782-fig-0063" title="">Analysis 4.14</a>). </p> </li> </ul> </p> <p>These analyses were based on one trial involving 2904 randomised participants followed for three months, and 2267 randomised participants followed for six months (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> </section> </section> </section> <section id="CD011782-sec-0101"> <h4 class="title">Secondary harm outcomes</h4> <p>Secondary harmful outcomes were inconsistently reported by the included studies. Data were mostly detailed only according to the number of participants experiencing a certain type of event. None of the included studies reported number of events. </p> <section id="CD011782-sec-0102"> <h5 class="title">Thrombocytopenia and heparin‐induced thrombocytopenia</h5> <p>The standard definition of thrombocytopenia is platelet count less than 150 x 10<sup>9</sup>/L, and heparin‐induced thrombocytopenia (HIT) is defined as a relative reduction in platelet count of about 50% (even if the platelet count at its lowest remains above 150 x 10<sup>9</sup>/L) occurring within 5 to 14 days after the start of heparin therapy (<a href="./references#CD011782-bbs2-0082" title="WarkentinTE , RobertsRS , HirshJ , KeltonJG . An improved definition of immune heparin‐induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine2003;163(20):2518–24. ">Warkentin 2003</a>), and should be confirmed through functional or immunological laboratory tests to detect platelet activation induced by anti‐platelet factor 4 antibodies (<a href="./references#CD011782-bbs2-0055" title="KeelingD , DavidsonS , WatsonH , Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. The management of heparin‐induced thrombocytopenia. British Journal of Haematology2006;133(3):259–69. ">Keeling 2006</a>). </p> <section id="CD011782-sec-0103"> <h6 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h6> <p>One trial measured platelet counts at baseline, day 4, and at the end of the trial (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). The definition used to classify thrombocytopenia was not documented. Heparin‐induced thrombocytopenia was defined as platelet count less than 100 x 10<sup>9</sup>/L or decreased more than 40% from the baseline. Laboratory tests were used to detect HIT antibodies, but were not described in detail. Seven participants in each treatment group developed thrombocytopenia. This represents a frequency of thrombocytopenia equal to approximately 0.64% in both groups. None of the thrombocytopenic participants were reported as having developed HIT antibodies, and none of the cases were associated with thromboembolism events. </p> </section> <section id="CD011782-sec-0104"> <h6 class="title">Other comparisons</h6> <p>Three trials did not report a definition for or data on thrombocytopenia and HIT (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>; <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). The <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a> stated that no events of HIT were observed, although no details on how HIT was assessed and diagnosed were provided in the trial report. </p> </section> </section> <section id="CD011782-sec-0105"> <h5 class="title">Other harmful effects: adverse effects leading to withdrawals or premature discontinuation of treatment </h5> <section id="CD011782-sec-0106"> <h6 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h6> <p>A total of 46 out of 2658 participants recruited to the <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> and <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a> prematurely discontinued treatment due to harmful effects (1.73%, 95% CI 1.3 to 2.30). However, the data were reported inconsistently, and were not detailed according to type of adverse effect and treatment harm. </p> <p>The <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> trial reported data according to treatment group, although without detailing the types of adverse effects (n = 2205). These additional data were available only in non‐published reports (<a href="./references#CD011782-bbs2-0045" title="GSK Trial Register. www.gsk‐clinicalstudyregister.com/study/EFC2441#rs (accessed 4 April 2017). ">GSK Trial Register</a>). We identified no clear difference in withdrawals due to harmful effects between treatment groups (RR 0.73, 95% CI 0.40 to 1.32; <a href="./references#CD011782-fig-0018" title="">Analysis 1.11</a>). </p> <p><a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a> reported that three participants withdrew from the trial due to harmful effects, but did not categorise these data. </p> </section> <section id="CD011782-sec-0107"> <h6 class="title">Idrabiotaparinux versus idraparinux</h6> <p>A total of 47 participants enrolled in the <a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a> trial discontinued treatment prematurely due to harmful effects. Withdrawals due to harmful effects appeared to occur with similar frequency in both treatment groups (RR 0.71, 95% CI 0.41 to 1.25; <a href="./references#CD011782-fig-0040" title="">Analysis 2.13</a>). The number of participants analysed was 757. </p> </section> <section id="CD011782-sec-0108"> <h6 class="title">LMWH and idraparinux versus standard therapy</h6> <p>A total of 58 participants treated with LMWH and idraparinux discontinued treatment due to bleeding and other harmful effects (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). The occurrence of all harmful effects leading to withdrawal appeared to follow a dose‐related curve: </p> <p> <ul id="CD011782-list-0034"> <li> <p>LMWH + idraparinux 2.5 mg (8/131): 6.11% (95% CI 3.13 to 11.60);</p> </li> <li> <p>LMWH + idraparinux 5.0 mg (15/135): 11.11% (95% CI 6.85 to 17.52);</p> </li> <li> <p>LMWH + idraparinux 7.5 mg (7/130): 5.38% (95% CI 2.63 to 10.70);</p> </li> <li> <p>LMWH + idraparinux 10.0 mg (28/131): 21.37% (95% CI 15.22 to 29.57).</p> </li> </ul> </p> <p>Eight of 132 participants receiving standard therapy discontinued treatment due to harmful effects (AR 6.06, 95% CI 3.10 to 11.5). There was no clear difference in withdrawals due to harmful effects between treatment groups (RR 1.82, 95% CI 0.89 to 3.71; <a href="./references#CD011782-fig-0049" title="">Analysis 3.8</a>). </p> <p>The number of participants analysed was 659.</p> </section> <section id="CD011782-sec-0109"> <h6 class="title">Idraparinux versus standard therapy</h6> <p>A total of 331 participants discontinued treatment prematurely in the trial providing data for this analysis (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> <p>The frequency of participants discontinuing treatment for any reason, including suspected lack of efficacy and adverse effects, was: </p> <p> <ul id="CD011782-list-0035"> <li> <p>total of 177 participants receiving idraparinux for three and six months, an estimated frequency of 12.19% (95% CI 10.61 to 13.97); </p> </li> <li> <p>total of 154 participants receiving standard therapy for three and six months, an estimated frequency of 10.60% (95% CI 9.13 to 12.3). </p> </li> </ul> </p> <p>The frequency of participants discontinuing treatment specifically due to harmful effects was: </p> <p> <ul id="CD011782-list-0036"> <li> <p>total of 103 participants receiving idraparinux for three and six months, an estimated frequency of 7.09% (95% CI 5.88 to 8.53); </p> </li> <li> <p>total of 65 participants receiving standard therapy for three and six months, an estimated frequency of 4.48% (95% CI 3.53 to 5.67). </p> </li> </ul> </p> <p>There was a greater occurrence of adverse effects leading to withdrawal in the idraparinux group (RR 1.58, 95% CI 1.17 to 2.14; <a href="./references#CD011782-fig-0064" title="">Analysis 4.15</a>). </p> <p>The number of participants for which data were analysed was 2904.</p> </section> </section> <section id="CD011782-sec-0110"> <h5 class="title">Other harmful effects: other harmful effects during follow‐up</h5> <section id="CD011782-sec-0111"> <h6 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h6> <p>Considering the 10 most frequently reported harmful effects in the <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> trial, the initial treatment of DVT with fondaparinux plus vitamin K antagonist appears to present with a similar safety profile to an initial treatment with LMWH (<a href="#CD011782-tbl-0008">Table 4</a>). The risk of a harmful effect was increased in the standard therapy group for two types of adverse effects: bruise (RR 0.38, 95% CI 0.18 to 0.81), and increased levels of hepatic enzymes (RR 0.08, 95% CI 0.03 to 0.21). The number of participants analysed was 2192. </p> <div class="table" id="CD011782-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Relative risks of the 10 most frequent harmful effects during the initial treatment with fondaparinux versus standard treatment (LMWH, enoxaparin, for 5 days)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harmful effect, n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fondaparinux (n = 1091)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Enoxaparin (n = 1101)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (2.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (2.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.56 to 1.58)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (1.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (2.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.38 to 1.14)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diarrhoea</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (1.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (2.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.36 to 1.32)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (1.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.44 to 1.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bruise</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (0.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 (0.18 to 0.81)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Haematoma</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.38 to 1.58)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (2.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (2.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.47 to 1.32)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hepatic enzymes increased</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (0.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (4.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (0.03 to 0.21)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SGPT increased</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 (4.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (0.01 to 0.18)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SGOT increased</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (2.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (0.00 to 0.24)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Headache</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (3.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (3.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.61 to 1.50)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coughing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (1.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (0.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.02 (0.82 to 4.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.62 (0.94 to 7.33)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Insomnia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (2.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (1.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.74 to 2.40)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Urinary tract infection</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (2.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (1.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.47 to 1.37)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval<br/> LMWH: low molecular weight heparin<br/> SGOT: serum glutamic oxaloacetic transaminase<br/> SGPT: serum glutamic pyruvic transaminase </p> </div> </div> <p>Pooling all the harmful effects reported to have occurred in the <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> trial (including adverse effects leading to premature discontinuation of the study medication), the profile of harmful effects favoured fondaparinux plus vitamin K antagonist (RR 0.84, 95% CI 0.76 to 0.93; <a href="./references#CD011782-fig-0019" title="">Analysis 1.12</a>); very low‐quality evidence. The <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> trial also reported serious adverse effects, including bleeding, and showed no clear difference between treatment groups (RR 1.24, 95% CI 0.84 to 1.84; <a href="./references#CD011782-fig-0020" title="">Analysis 1.13</a>) </p> <p>The number of participants analysed was 2205 (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a> did not report data on harmful effects. </p> </section> <section id="CD011782-sec-0112"> <h6 class="title">Idrabitaparinux versus idraparinux</h6> <p>Treatment with idrabiotaparinux and idraparinux appears to be comparable in terms of harmful effects (<a href="#CD011782-tbl-0009">Table 5</a>). Pooled analysis of all harmful effects (leading to premature discontinuation or occurring during follow‐up) did not show a clear difference in the incidence of harmful effects when comparing both interventions (RR 0.92, 95% CI 0.83 to 1.02; <a href="./references#CD011782-fig-0041" title="">Analysis 2.14</a>); very low‐quality evidence. </p> <div class="table" id="CD011782-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Relative risks of harmful effects induced by idrabiotaparinux versus idraparinux</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harmful effects, n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idrabiotaparinux</b> </p> <p><b>(n = 385)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idraparinux</b> </p> <p><b>(n = 370)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223 (57.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 (61.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.84 to 1.06)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infections and infestations</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (17.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 (22.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.59 to 1.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (3.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.66 to 4.14)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urinary tract infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.36 to 2.53)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bronchitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.26 to 1.75)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (1.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.25 to 2.06)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Musculoskeletal and connective tissue disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (12.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (11.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.73 to 1.57)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain in extremity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (3.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35 (0.61 to 2.99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arthralgia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.31 to 1.93)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (10.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (13.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.54 to 1.19)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (2.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08 (0.42 to 2.77)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vascular disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (10.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (9.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.71 to 1.69)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (3.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (5.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.37 to 1.39)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (2.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.54 to 1.19)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Injury, poisoning, and procedural complications</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (9.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (11.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.55 to 1.25)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Accidental overdose*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (5.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (3.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.55 (0.79 to 3.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fall</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (1.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (3.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 (0.14 to 1.13)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nervous system disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (9.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (8.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (0.73 to 1.79)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (4.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (4.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.22 (0.63 to 2.36)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General disorders and administration site conditions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (8.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (11.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.51 to 1.19)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oedema peripheral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (3.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52 (0.21 to 1.28)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory, thoracic, and mediastinal disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (8.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (7.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.66 to 1.72)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epistaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (3.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.66 to 4.14)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Overdose is defined as two or more injections of the study drug in five days or fewer.</p> <p>CI: confidence interval</p> </div> </div> <p>The number of participants analysed was 757 (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>). </p> </section> <section id="CD011782-sec-0113"> <h6 class="title">LMWH and idraparinux versus standard therapy</h6> <p>Data on harmful effects were not provided for any of the treatment groups. The published report stated that "adverse effects were distributed similarly between the groups" (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). Nevertheless, the trial reports an increase in the alanine aminotransferase during treatment with LMWH (15%, only relative frequency reported), and in participants later allocated to receive idraparinux (0.8%, one participant). </p> </section> <section id="CD011782-sec-0114"> <h6 class="title">Idraparinux versus standard therapy</h6> <p>Apart from bleeding, the following data on harmful effects were reported: cancer, cardiac failure, rash, dermatitis or urticaria, infection, and other events. The risk of cardiac failure was elevated in participants receiving standard therapy in comparison with those treated with idraparinux (RR 0.33, 95% CI 0.13 to 0.84) (<a href="#CD011782-tbl-0010">Table 6</a>). Grouping all harmful effects except bleeding, there was no clear difference in the risk of harmful effects among participants treated with standard therapy in comparison with those receiving idraparinux (RR 1.03, 95% CI 1.00 to 1.06; <a href="./references#CD011782-fig-0065" title="">Analysis 4.16</a>); very low‐quality evidence. </p> <div class="table" id="CD011782-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Relative risks of harmful effects induced by idraparinux versus standard therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects, n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idraparinux</b> </p> <p><b>(n = 1452)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Standard therapy (n = 1452)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (6.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (6.27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.81 to 1.41)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (0.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (1.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.13 to 0.84)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash, dermatitis, or urticaria</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (4.27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (3.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35 (0.93 to 1.96)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (18.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295 (20.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.76 to 1.03)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>778 (53.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>754 (51.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.96 to 1.11)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval</p> </div> </div> <p>The number of participants contributing data was 2904 (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> </section> </section> </section> <section id="CD011782-sec-0115"> <h4 class="title">Assessment of reporting bias</h4> <p>We could not assess reporting bias due to the insufficient number of trials (fewer than 10). </p> </section> <section id="CD011782-sec-0116"> <h4 class="title">Subgroup analysis</h4> <p>Two studies presented data permitting us to perform subgroup analysis for two treatment comparisons: </p> <p> <ul id="CD011782-list-0037"> <li> <p>fondaparinux plus vitamin K antagonist versus standard therapy (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>); </p> </li> <li> <p>idraparinux versus standard therapy (<a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). </p> </li> </ul> </p> <section id="CD011782-sec-0117"> <h5 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h5> <p>The <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> study published data on participants of different weight categories as well as on participants with active cancer and undergoing outpatient treatment. We were able to perform subgroup analyses comparing the following categories: </p> <p> <ul id="CD011782-list-0038"> <li> <p>participants weighing less than 50 kg versus participants weighing between 50 kg and 100 kg and participants weighing more than 100 kg; </p> </li> <li> <p>participants receiving inpatient versus outpatient treatment; and</p> </li> <li> <p>participants with no cancer versus participants with active cancer.</p> </li> </ul> </p> <section id="CD011782-sec-0118"> <h6 class="title">Obese participants</h6> <p>The <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> trial included 2205 participants, who were categorised according to body weight as follows: </p> <p> <ul id="CD011782-list-0039"> <li> <p>55 participants (2.5%) had body weight less than 50 kg;</p> </li> <li> <p>1922 participants (87.2%) had body weight between 50 kg and 100 kg; and</p> </li> <li> <p>228 participants (10.3%) had body weight greater than 100 kg.</p> </li> </ul> </p> <p>Data on recurrent VTE and on major bleeding were reported according to the body weight subgroups. </p> <p>The pooled analysis was relatively imprecise: the risk of VTE between intervention groups did not show a clear variation according to body weight (RR 0.26, 95% CI 0.03 to 2.33 for participants with body weight less than 50 kg; RR 0.97, 95% CI 0.63 to 1.51 for participants with body weight between 50 kg and 100 kg; and RR 1.53, 95% CI 0.37 to 6.24 for participants with body weight greater than 100 kg; I<sup>2</sup> = 0%, test for subgroup differences: P = 0.41; <a href="./references#CD011782-fig-0021" title="">Analysis 1.14</a>; <a href="#CD011782-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD011782-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.12 Recurrent VTE at 3 months' follow‐up [body weight]." data-id="CD011782-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.12 Recurrent VTE at 3 months' follow‐up [body weight]. </p> </div> </div> </div> <p>Major bleeding occurred in one participant with body weight less than 50 kg in the fondaparinux plus vitamin K antagonist group, and in one participant with body weight greater than 100 kg in the standard therapy group. We could not estimate the comparative risk due to the sparse number of cases. </p> </section> <section id="CD011782-sec-0119"> <h6 class="title">Outpatient treatment</h6> <p>In the <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> study, 345 of the participants randomised to the fondaparinux plus vitamin K antagonist group and 374 of the participants randomised to the standard therapy group received outpatient treatment. We detected no clear difference in the risk of recurrent VTE at three months' follow‐up between participants receiving outpatient treatment in comparison with participants receiving inpatient treatment (RR 1.21, 95% CI 0.75 to 1.95; and RR 0.47, 95% CI 0.20 to 1.14, respectively; test for subgroup differences: I<sup>2</sup> = 70.4%, P = 0.07; <a href="./references#CD011782-fig-0022" title="">Analysis 1.15</a>). </p> <p>People receiving outpatient treatment appeared to experience more major bleeding events than people receiving inpatient treatment, comparing treatment with fondaparinux plus vitamin K antagonist to standard therapy. We detected a difference in the risk of major bleeding at three months' follow‐up between participants receiving inpatient treatment in comparison with participants receiving outpatient treatment (RR 0.68, 95% CI 0.26 to 1.78; and RR 4.34, 95% CI 1.23 to 15.24, respectively; test for subgroup differences: I<sup>2</sup> = 81%, P = 0.02; <a href="./references#CD011782-fig-0023" title="">Analysis 1.16</a>). </p> </section> <section id="CD011782-sec-0120"> <h6 class="title">Cancer patients</h6> <p>In the <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> study, a subgroup of 126 participants randomised to fondaparinux plus vitamin K antagonist and 111 participants randomised to standard therapy had active cancer. We detected a difference in the risk of recurrent VTE at three months' follow‐up between participants with no cancer (RR 0.71, 95% CI 0.44 to 1.14) in comparison with participants with active cancer (RR 2.35, 95% CI 0.95 to 5.79) (test for subgroup differences: I<sup>2</sup> = 81.2%, P = 0.02; <a href="./references#CD011782-fig-0024" title="">Analysis 1.17</a>). People with active cancer appeared to experience an inferior beneficial effect when treated with fondaparinux plus vitamin K antagonist in comparison with treatment with standard therapy. </p> <p>Major and clinically relevant bleeding did not appear to differ in participants with no cancer (RR 0.94, 95% CI 0.68 to 1.31) in comparison with participants with active cancer (RR 1.06, 95% CI 0.62 to 1.81) (test for subgroup difference: I<sup>2</sup> = 0%, P = 0.73; <a href="./references#CD011782-fig-0025" title="">Analysis 1.18</a>). The results were slightly inconsistent when analysing the categories of major bleeding and clinically relevant bleeding. The risk of major bleeding in people receiving fondaparinux plus vitamin K antagonist and those receiving standard therapy for three months did not appear to vary between people with no cancer (RR 1.08, 95% CI 0.57 to 2.04) and people with active cancer (RR 0.99, 95% CI 0.40 to 2.48) (test for subgroup differences: I<sup>2</sup> = 0%, P = 0.89; <a href="./references#CD011782-fig-0026" title="">Analysis 1.19</a>), while the risk of clinically relevant bleeding in people receiving fondaparinux plus vitamin K antagonist and those receiving standard therapy for three months varied between people with no cancer (RR 3.82, 95% CI 2.03 to 7.18) and people with active cancer (RR 1.10, 95% CI 0.54 to 2.25) (test for subgroup difference: I<sup>2</sup> = 84.7%, P = 0.01; <a href="./references#CD011782-fig-0027" title="">Analysis 1.20</a>). </p> </section> </section> <section id="CD011782-sec-0121"> <h5 class="title">Idraparinux versus standard therapy</h5> <p>The <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a> trial presented data on the group of participants with active cancer. We extracted these data as reported by <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a> and were able to calculate the comparative data on the group of participants without active cancer. A total of 146 participants treated with idraparinux and 138 participants treated with standard therapy had active cancer (n = 284). Clinicians allocated a subgroup of 140 participants treated with LMWH and idraparinux and 130 participants treated with standard therapy to receive treatment for six months; the others were treated for three months. </p> <p>The specific publication detailing these data had several inconsistencies. For instance, data reported in the text differed from data reported in the tables for the primary efficacy outcome (VTE), and it was stated that data for some major and clinically relevant bleeding were not shown, when the data were clearly presented in a table. We therefore only analysed data for the primary efficacy outcome to avoid major data mistakes. </p> <section id="CD011782-sec-0122"> <h6 class="title">Cancer patients</h6> <p>The risk of recurrent VTE in people receiving idraparinux and those receiving standard therapy for three months did not appear to be modified by the presence of active cancer (RR 1.20, 95% CI 0.75 to 1.92 for participants without cancer; and RR 0.43, 95% CI 0.15 to 1.20 for participants with active cancer; test for subgroup differences: P = 0.08; <a href="./references#CD011782-fig-0066" title="">Analysis 4.17</a>). </p> <p>The risk of recurrent VTE in people receiving idraparinux and those receiving standard therapy for six months appeared to be modified by the presence of active cancer (RR 1.25, 95% CI 0.78 to 2.01 for participants without cancer; and RR 0.39, 95% CI 0.14 to 1.07 for participants with active cancer; test for subgroup difference: P = 0.04; <a href="./references#CD011782-fig-0067" title="">Analysis 4.18</a>). If these results are proven to be accurate in a larger sample of participants receiving treatment after controlling for confounding, then one could expect participants with active cancer to experience a larger benefit from treatment with idraparinux (I<sup>2</sup> = 76.3%). </p> <p>The results at both three and six months were uncertain due to inconsistencies in the trial report for the subgroup of participants with active cancer. </p> </section> </section> </section> <section id="CD011782-sec-0123"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform a sensitivity analysis for most of the comparisons only one study contributed data. One comparison was supported by data from two studies: fondaparinux plus vitamin K antagonist versus standard therapy (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). We observed similar results after excluding one of the studies from the analysis (data not shown). </p> <p>We performed an additional sensitivity analysis to investigate the potential impact of missing data on harmful effects on the results. We confirmed that imputing a 'worst‐case scenario' did not change the results. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011782-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011782-sec-0124">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011782-sec-0178">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011782-sec-0124"></div> <section id="CD011782-sec-0125"> <h3 class="title" id="CD011782-sec-0125">Summary of main results</h3> <p>The use of the pentasaccharide fondaparinux is currently an option for the prevention of DVT and pulmonary embolism in non‐surgical and surgical patients (<a href="./references#CD011782-bbs2-0043" title="GouldMK , GarciaDA , WrenSM , KaranicolasPJ , ArcelusJI , HeitJA , et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e227S‐77S. ">Gould 2012</a>; <a href="./references#CD011782-bbs2-0052" title="KahnSR , LimW , DunnAS , CushmanM , DentaliF , AklEA , et al. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e195S‐226S. ">Kahn 2012</a>), including orthopaedic surgical patients (<a href="./references#CD011782-bbs2-0035" title="Falck‐YtterY , FrancisCW , JohansonNA , CurleyC , DahlOE , SchulmanS , et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e278S‐325S. ">Falck‐Ytter 2012</a>). In this review, we have complemented this information with the evidence on the usefulness of pentasaccharides to treat DVT by analysing a group of studies investigating the effects of the pentasaccharides fondaparinux, idraparinux, and idrabiotaparinux. We found moderate‐quality evidence that the effectiveness/risk balance of fondaparinux is similar to standard therapy. This means that fondaparinux is as effective as the standard treatment in reducing the recurrence of VTE in people treated for DVT, and shows similar rates of major bleeding, the main harmful effect associated with anticoagulant treatment. Moderate‐quality evidence means that this estimate is likely to be true, though it remains possible that new research could demonstrate it to be different. </p> <p>Nevertheless, we were disappointed with the paucity of evidence comparing pentasaccharides and the standard treatment with LMWH or unfractionated heparin followed by vitamin K antagonists for DVT. We identified only five studies, which comprised four direct comparisons between one of these new anticoagulants and the typical therapy. Remarkably, the biotinylated molecule of idraparinux, idrabiotaparinux, the only pentasaccharide with a currently available antidote to reverse its anticoagulant effect, has never been directly compared to the standard treatment. </p> <p>The five studies included in this review encompassed a parallel design and were reported in 18 different publications. Data of 6981 participants were available from these studies. We assessed recurrent VTE as our primary efficacy outcome and bleeding as our primary harm outcome according to the reported comparisons between the pentasaccharides and standard or alternative therapies. We had planned to assess recurrent VTE after six months of treatment. However, some studies only reported data at three months' follow‐up, therefore in each case we considered the follow‐up reported by the studies. Our secondary outcomes for efficacy and harms included: all‐cause mortality, recurrent DVT, pulmonary embolism, thrombocytopenia and heparin‐induced thrombocytopenia, and other harmful effects. </p> <section id="CD011782-sec-0126"> <h4 class="title">Primary outcomes</h4> <section id="CD011782-sec-0127"> <h5 class="title">Recurrent VTE</h5> <p>Results from the meta‐analyses demonstrated no clear difference between the risk of recurrent VTE in participants receiving fondaparinux or lower doses of the long‐action pentasaccharides in comparison with those receiving standard therapy. Nevertheless, our confidence in these estimates was ranged from moderate to very low. The treatment duration in the included studies varied from three months, in <a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a> and <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>, to six months (<a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a>; <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>; <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). The <a href="./references#CD011782-bbs2-0001" title="BullerHR , DestorsJM , GallusAS , PrinsMH , RaskobGE . Idrabiotaparinux, a biotinylated long‐acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX Study): safety, efficacy, and reversibility by avidin [Abstract No. 32]. Blood2009; Vol. 112:18. Equinox Investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. Journal of Thrombosis and Haemostasis2011;9(1):92‐9. NCT00311090 . Bioequipotency study of SSR126517E and idraparinux in patients with deep venous thrombosis of the lower limbs (EQUINOX). clinicaltrials.gov/ct2/show/NCT00311090 (first received 5 April 2006). ">EQUINOX</a> trial included three months of additional follow‐up after the six months of treatment (total follow‐up of nine months). </p> <section id="CD011782-sec-0128"> <h6 class="title">Fondaparinux</h6> <p>Our analysis demonstrated that fondaparinux followed by vitamin K antagonists offers similar benefits of the standard therapy in the treatment of DVT. Participants were followed up to three months. We judged the quality of the evidence as moderate, which means that we are confident in the results, though the possibility remains that new research could change the estimates. The studies included in this analysis enrolled participants with similar demographic characteristics at baseline, and pooled analysis showed no important heterogeneity (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0004" title="The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti‐factor Xa activity: a phase II evaluation. Circulation2000;102(22):2726‐31. ">Rembrandt Trial</a>). </p> </section> <section id="CD011782-sec-0129"> <h6 class="title">Idraparinux and idrabiotaparinux</h6> <p>The studies analysing the effect of idraparinux and its biotinylated molecule, idrabiotaparinux, included diverse comparisons and could not be pooled in one meta‐analysis. </p> <p>Idraparinux (2.5 mg) showed no clear difference with an equimolar dose of idrabiotaparinux (3.0 mg) in preventing recurrence of VTE at six and nine months' follow‐up. We judged the evidence as low quality, which means that we have limited confidence in the results. </p> <p>Two trials, <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a> and <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>, appeared to have included two similar intervention groups, which could have allowed us to pursue a pooled analysis comparing treatment with 2.5 mg of idraparinux with the standard therapy. However, the treatments actually tested in these studies differed from one another (<a href="#CD011782-tbl-0007">Table 3</a>). Participants assigned to the intervention group in the <a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a> received five to seven days of enoxaparin before being randomised to receive one of three different doses of idraparinux. Participants enrolled in the intervention group of the <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a> trial were treated with idraparinux from day one until the end of the follow‐up. For this reason, we did not perform a pooled analysis with the data available from these studies. </p> <p>We found no clear difference between treatment with LMWH followed by 10 mg of idraparinux versus standard therapy in the prevention of recurrent VTE at three months' follow‐up. We considered the quality of the evidence to be very low, meaning that we have limited confidence in the validity of the evidence. The results from the single trial providing data for this analysis were influenced by the significant amount of missing outcome data due to exclusions, withdrawals, and loss to follow‐up (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). Moreover, participants were excluded due to presumed lack of efficacy (suspected VTE). The low number of accumulated cases of recurrent VTE in the group receiving doses of 2.5 mg, 5.0 mg, and 7.5 mg of idraparinux prevented any quantitative analysis. </p> <p>Treatment with idraparinux from day one demonstrated similar efficacy to the standard treatment in the prevention of recurrent VTE at three and six months' follow‐up. We assessed the quality of the evidence at three months' follow‐up as low, which limits our confidence in the validity of the evidence. </p> </section> </section> <section id="CD011782-sec-0130"> <h5 class="title">Bleeding</h5> <section id="CD011782-sec-0131"> <h6 class="title">Fondaparinux</h6> <p>Moderate‐quality evidence showed no clear difference in major bleeding between the two intervention groups for the initial five days of treatment and at three months' follow‐up. The estimated heterogeneity for the analysis of major bleeding was not important. Only one trial reported clinically relevant bleeding, showing similar frequencies comparing participants treated with fondaparinux to participants receiving standard therapy for the initial five days of treatment and at three months' follow‐up. </p> <p>Overall, the absolute risk of bleeding exceeded 1% in both treatment groups for the initial five days of treatment and at three months' follow‐up. An adverse effect occurring in more than 1% of those exposed to the treatment is considered a common and frequent event (<a href="./references#CD011782-bbs2-0085" title="World Health Organization (WHO). Glossary of pharmacovigilance terms. https://www.who‐umc.org/global‐pharmacovigilance/global‐pharmacovigilance/glossary/ (accessed 15 November 2017). ">WHO 2011</a>), therefore although we can be moderately confident that bleeding rates associated with fondaparinux are similar to those associated with standard therapy, the frequency of this harmful effect continues to be a concern in people receiving anticoagulant therapy. </p> </section> <section id="CD011782-sec-0132"> <h6 class="title">Idraparinux and idrabiotaparinux</h6> <p>Overall, we found that participants treated with idrabiotaparinux showed a higher risk of bleeding in comparison with those treated with idraparinux. We judged the quality of the evidence as low, which limits our conclusions. Data on the use of avidin were not reported. The higher frequency of major and clinically relevant bleeding in participants receiving idrabiotaparinux remained three months after participants stopped treatment (nine months of follow‐up). </p> <p>The incidence of major and clinically relevant bleeding in participants receiving LMWH followed by idraparinux at three months' follow‐up demonstrated a clear dose‐response relationship when compared to participants receiving standard therapy. The risk of bleeding in participants receiving doses of 10 mg of idraparinux was six times the risk of bleeding in those treated with 2.5 mg of idraparinux. Overall, when participants receiving LMWH and any dose of idraparinux were combined, there was no clear difference in bleeding between the idraparinux group and the standard therapy group. The absolute risk (incidence) of bleeding was superior to the expected incidence in both groups (expected incidence of bleeding range from 0.9% to 2.2%) (<a href="./references#CD011782-bbs2-0049" title="HuttenBA , LensingAW , KraaijenhagenRA , PrinsMH . Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging1999;14(4):303‐12. ">Hutten 1999</a>). The high frequency of bleeding was responsible for the withdrawal of 17 participants (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>). Only participants receiving the lower dose of 2.5 mg of idraparinux presented with an absolute risk of bleeding comparable to the standard therapy. We considered the quality of the evidence related to the outcome of major bleeding to be very low, which means that the estimates are largely imprecise. </p> <p>Participants receiving 2.5 mg of idraparinux from day one in comparison with those receiving standard therapy showed a slightly lower overall risk of major and clinically relevant bleeding at three months' follow‐up. We found very low‐quality evidence showing no clear difference in major bleeding between participants receiving 2.5 mg of idraparinux and those receiving standard treatment, so we cannot draw any precise conclusions. There was also no clear difference in major bleeding between interventions at six months' follow‐up. </p> </section> </section> </section> <section id="CD011782-sec-0133"> <h4 class="title">Secondary outcomes</h4> <section id="CD011782-sec-0134"> <h5 class="title">All‐cause mortality</h5> <p>The analyses of all‐cause mortality were expected to complement the results of the primary outcome 'recurrence of VTE'. In this regard, the results for all‐cause mortality were consistent with those of the primary efficacy outcome recurrent VTE for all of the following comparisons, that is there was no clear difference in the frequency of mortality between the compared interventions: </p> <p> <ul id="CD011782-list-0040"> <li> <p>fondaparinux plus vitamin K antagonist versus standard therapy (three months of follow‐up, two trials); </p> </li> <li> <p>idrabiotaparinux versus idraparinux (six and nine months of follow‐up, one trial); and </p> </li> <li> <p>idraparinux versus standard therapy (three and six months of follow‐up, one trial).</p> </li> </ul> </p> <p>The comparison of LMWH and idraparinux versus standard therapy did not allow further analyses due to sparse number of cases. </p> <p>We considered the evidence on all‐cause mortality to be of moderate quality for the comparison of fondaparinux plus vitamin K antagonist versus standard therapy. We found substantial statistical heterogeneity in this analysis, which could be explained by differences in participants between studies and missing data across studies. We judged the quality of the evidence as low for the comparisons of idrabiotaparinux versus idraparinux (six months' follow‐up) and idraparinux versus standard therapy (three months' follow‐up). </p> </section> <section id="CD011782-sec-0135"> <h5 class="title">Recurrent DVT</h5> <p>The risk of recurrent DVT appears to be similar in the following groups:</p> <p> <ul id="CD011782-list-0041"> <li> <p>participants receiving fondaparinux plus vitamin K antagonist compared to those receiving standard therapy at three months' follow‐up; </p> </li> <li> <p>participants receiving idrabiotaparinux compared to those receiving idraparinux at six months' follow‐up; and </p> </li> <li> <p>participants treated with idraparinux compared to those receiving standard treatment at three and six months' follow‐up. </p> </li> </ul> </p> <p>Data for these analyses were extracted from single studies and no meta‐analysis was performed. The confidence intervals for all comparisons were wide, thus highlighting the imprecision of these estimates. No data were available to compare the risk of recurrent DVT in people receiving LMWH and idraparinux in comparison with standard therapy. </p> </section> <section id="CD011782-sec-0136"> <h5 class="title">Pulmonary embolism</h5> <p>There was a similarity between the results for the risk of pulmonary embolism and those for the risk of DVT. There was no clear difference in the risk of pulmonary embolism when considering (i) fondaparinux plus vitamin K antagonist compared to standard treatment (three months of follow‐up), (ii) idrabiotaparinux versus idraparinux (six months of follow‐up), and (iii) idraparinux versus standard therapy (three and six months of follow‐up). Data for these analyses were extracted from single studies and no meta‐analysis was performed. The confidence intervals for all comparisons were wide, thus highlighting imprecision of these estimates. No data were available to compare the risk of recurrent pulmonary embolism in people receiving LMWH and idraparinux in comparison with standard treatment. </p> </section> </section> <section id="CD011782-sec-0137"> <h4 class="title">Secondary harm outcomes</h4> <section id="CD011782-sec-0138"> <h5 class="title">Thrombocytopenia and heparin‐induced thrombocytopenia</h5> <p>Heparin‐induced thrombocytopenia (HIT) is a life‐threatening condition and a relatively common harmful effect induced by heparin (<a href="./references#CD011782-bbs2-0051" title="JunqueiraDR , ZorzelaLM , PeriniE . Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD007557.pub3] ">Junqueira 2017</a>). It is defined as a relative reduction in platelet count of about 50% (even if the platelet count at its lowest remains above 150 x 10<sup>9</sup>/L) occurring within 5 to 14 days after the start of heparin therapy (<a href="./references#CD011782-bbs2-0082" title="WarkentinTE , RobertsRS , HirshJ , KeltonJG . An improved definition of immune heparin‐induced thrombocytopenia in postoperative orthopedic patients. Archives of Internal Medicine2003;163(20):2518–24. ">Warkentin 2003</a>). It is an immune‐mediated reaction induced by the heparin and frequently followed by venous or arterial thrombosis (<a href="./references#CD011782-bbs2-0050" title="JunqueiraDR , CarvalhoMG , PeriniE . Heparin‐induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction. Revista da Associação Médica Brasileira2013;59(2):161‐6. ">Junqueira 2013</a>). In postoperative patients, the incidence of HIT is estimated to be 2.3% in patients exposed to unfractionated heparin and equal to 0.4% in patients treated with LMWH (<a href="./references#CD011782-bbs2-0051" title="JunqueiraDR , ZorzelaLM , PeriniE . Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD007557.pub3] ">Junqueira 2017</a>). </p> <p>Fondaparinux binds with platelet factor 4 forming the fondaparinux‐platelet factor 4, which is similar to the heparin‐platelet factor 4 responsible for inducing the formation of HIT antibodies (<a href="./references#CD011782-bbs2-0083" title="WarkentinTE , SheppardJI , SunJC , JungH , EikelboomJW . Anti‐PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. Journal of Thrombosis and Haemostasis2013;11(2):253‐60. ">Warkentin 2013</a>). However, it appears that fondaparinux is unable to induce platelet activation in the presence of HIT antibodies (<a href="./references#CD011782-bbs2-0071" title="SaviP , ChongBH , GreinacherA , GruelY , KeltonJG , WarkentinTE , et al. Effect of fondaparinux on platelet activation in the presence of heparin‐dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood2005;105(1):139‐44. ">Savi 2005</a>), and only a few cases of HIT associated with fondaparinux have been reported (<a href="./references#CD011782-bbs2-0017" title="BhattVR , AryalMR , ShresthaR , ArmitageJO . Fondaparinux‐associated heparin‐induced thrombocytopenia. European Journal of Haematology2013;91(5):437‐41. ">Bhatt 2013</a>). </p> <p>We identified only one study reporting outcomes concerning the effect of pentasaccharides on platelets counts (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>). This is very disappointing since there is a need for further studies evaluating the role of fondaparinux in the treatment of HIT (<a href="./references#CD011782-bbs2-0058" title="LinkinsLA , DansAL , MooresLK , BonaR , DavidsonBL , SchulmanS , et al. Treatment and prevention of heparin‐induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e495S‐530S. ">Linkins 2012</a>). The incidence of thrombocytopenia defined as platelet count less than 100 x 10<sup>9</sup>/L or decreased by more than 40% from the baseline was equal to 0.64% in the group receiving fondaparinux plus vitamin K antagonist and in the group receiving LMWH. When the above definition for thrombocytopenia was associated with HIT antibodies detected by laboratory tests, no case of HIT was identified in 1098 participants exposed to fondaparinux plus vitamin K antagonist. Nevertheless, the laboratory test used was not reported. These results are in partial agreement with the commercial package insert of fondaparinux, which does not mention HIT but describes the occurrence of moderate thrombocytopenia (reduction of platelet counts between 100 x 10<sup>9</sup>/L and 50 x 10<sup>9</sup>/L) in 0.5% of participants receiving fondaparinux for the treatment of DVT (<a href="./references#CD011782-bbs2-0041" title="Food and Drug Administration (FDA). Fondaparinux (Arixtra®) package insert. Research Triangle Park, NC: GlaxoSmithKline, 2001. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021345 (accessed 31 August 2017). ">GlaxoSmithKline 2011</a>). Severe thrombocytopenia (platelet count lower than 50 x 10<sup>9</sup>/L) is also reported as occurring in 0.04% of these participants, though this was not reported in the published trials. </p> <p>It is unfortunate that underreporting and biased evidence prevent us from drawing definitive conclusions. The occurrence of thrombocytopenia and HIT appears to be rare in patients treated with fondaparinux. However, had we been able to extract and analyse unbiased evidence, this could have significantly reinforced the potential of fondaparinux not just as a treatment option for HIT (<a href="./references#CD011782-bbs2-0013" title="BadgerNO . Fondaparinux (Arixtra®), a safe alternative for the treatment of patients with heparin‐induced thrombocytopenia?. Journal of Pharmacy Practice2010;23(3):235‐8. ">Badger 2010</a>; <a href="./references#CD011782-bbs2-0053" title="KangM , AlahmadiM , SawhS , KovacsMJ , Lazo‐LangnerA . Fondaparinux for the treatment of suspected heparin‐induced thrombocytopenia: a propensity score‐matched study. Blood2015;125(6):924‐9. ">Kang 2015</a>), but also as a safer alternative to heparins. </p> </section> <section id="CD011782-sec-0139"> <h5 class="title">All harmful effects</h5> <p>Notably, the reporting of harmful effects was inconsistent and incomplete. We could perform meta‐analysis only by combining data on all harmful effects. Participants withdrawing from treatment were mostly not detailed according to the randomised treatment and reasons leading to withdrawal. </p> <p>The available data showed that the proportion of participants withdrawing due to harmful effects from the fondaparinux plus vitamin K antagonist group and the standard treatment group was comparable. However, a higher risk of bruising and increased levels of hepatic enzymes were observed in the group treated with standard therapy. The overall risk of all harmful effects was similar in the fondaparinux plus vitamin K antagonist group in comparison to the standard therapy group. We deemed the quality of the evidence as very low, so our confidence in the validity of these estimates is limited. </p> <p>The proportion of participants withdrawing due to harmful effects from the idrabiotaparinux group and the idraparinux group was comparable. The overall risk of any harmful effect was also similar in both groups. We judged the quality of the evidence as very low, which limits our conclusions. </p> <p>Comparing the frequency of harmful effects leading to withdrawal in participants receiving LMWH and idraparinux with those receiving standard treatment demonstrated a clear dose‐response relationship, with the lower dose of 2.5 mg idraparinux inducing an almost seven‐fold reduced frequency of harms. Withdrawals due to harmful effects appeared to occur with similar frequencies when comparing participants receiving all doses of idraparinux with participants receiving standard therapy. Data on all harmful effects were not reported for this comparison. </p> <p>Treatment with idraparinux from the first day was associated with higher frequencies of dropouts when compared to standard therapy. Data of very low quality from one single study contrasting idraparinux with standard therapy did not identify a clear difference in the occurrence of all harms in participants treated with idraparinux in comparison with those treated with standard therapy followed for three months. For this analysis, although the confidence interval could suggest a difference between the treatment groups, the limitations of inconsistency and incompleteness regarding the data on harmful outcomes combined with the low point estimate for the risk ratio means that any difference could have been detected by chance. </p> </section> </section> <section id="CD011782-sec-0140"> <h4 class="title">Subgroup analysis</h4> <p>Data evaluating the benefits and harmful effects of anticoagulant treatment in obese and cancer patients are frequently scarce. In our review, two studies reported extractable data on obese participants, participants with cancer, and also on participants treated as outpatients/inpatients (<a href="./references#CD011782-bbs2-0002" title="A multicentre, randomized, double‐blind study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus twice daily (b.i.d.) enoxaparin in the initial treatment of acute symptomatic deep vein thrombosis (DVT) (MATISSE‐DVT). Study No: EFC2441. GlaxoSmithKline Clinical Trial Register2005. BullerH . Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra): The MATISSE trials. Journal of Thrombosis and Haemostasis2005; Vol. 3, issue 1:Abstract number: P1112. BullerH , DavidsonB , DecoususH , GallusA , GentM , PiovellaF . Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. A randomized trial. Revue de Medecine Interne2005;26(1):82‐3. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Annals of Internal Medicine2004;140(11):867‐73. BullerHR , The MATISSE Investigators. Efficacy and safety of fondaparinux (ARIXTRA®) in the initial treatment of venous thromboembolism in obese patients. Blood2004; Vol. 104, issue 11:Abstract 706. BullerHR , The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra®): the Matisse trials. Blood2004; Vol. 104, issue 11:Abstract 705. The Matisse Investigators. The MATISSE‐DVT trial, a randomized, double‐blind study comparing once‐daily fondaparinux (Arixtra) with the low‐molecular‐weight heparin (LMWH) enoxaparin, twice daily, in the initial treatment of symptomatic deep‐vein thrombosis (DVT). Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract OC332. vanDoormaalFF , RaskobGE , DavidsonBL , DecoususH , GallusA , LensingAW , et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thrombosis and Haemostasis2009;101(4):762‐9. ">MATISSE‐DVT</a>; <a href="./references#CD011782-bbs2-0005" title="BullerHR , The Van Gogh Investigators. Evaluation of once weekly subcutaneous idraparinux versus standard therapy with heparin and vitamin K antagonists in the treatment of deep‐vein thrombosis or pulmonary embolism. Blood2006;108(11):6‐7. The Van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. vanDoormaalFF , CohenAT , DavidsonBL , DecoususH , GallusAS , GentM , et al. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thrombosis and Haemostasis2010;104:86‐91. ">Van Gogh Trial‐DVT</a>). Nevertheless, these studies addressed different comparisons and thus could not be pooled. </p> <section id="CD011782-sec-0141"> <h5 class="title">Fondaparinux plus vitamin K antagonist versus standard therapy</h5> <p>Our analyses suggest that participants with body weight greater than 100 kg appear to experience a reduced beneficial effect of the treatment with fondaparinux plus vitamin K antagonist in comparison with standard therapy when compared to participants weighing less than 50 kg and those weighing between 50 kg and 100 kg. The frequency of bleeding in participants with body weight greater than 100 kg in relation to participants weighing less than 100 kg could not be estimated due to sparse number of cases. Despite the limitations of any subgroup analysis, this evidence suggests that the anticoagulation effect of fondaparinux may vary with body weight and that reduced efficacy could be expected in obese patients. </p> <p>The beneficial and harmful effects of treatment with fondaparinux plus vitamin K antagonist in comparison with standard therapy appear to differ between people receiving outpatient care and those receiving inpatient treatment. There was no clear difference in beneficial effect between fondaparinux and standard therapy in participants receiving outpatient treatment in comparison to participants receiving inpatient treatment. However, participants receiving outpatient treatment appeared to experience more major bleeding events when treated with fondaparinux versus standard therapy than people receiving inpatient treatment. Fondaparinux may therefore present a poor effectiveness/risk balance in the treatment of people receiving outpatient care. </p> <p>There were reduced benefits in the treatment of DVT in participants with cancer treated with fondaparinux plus vitamin K antagonist for three months in comparison with participants who did not have cancer. The risk of major bleeding appeared to be similar in participants with and without cancer independent of the treatment, while clinically relevant bleeding appeared to be greater in people with cancer treated with fondaparinux plus vitamin K antagonist than in people without cancer. </p> </section> <section id="CD011782-sec-0142"> <h5 class="title">Idraparinux versus standard therapy</h5> <p>The risk of recurrent VTE in people receiving idraparinux and standard therapy for three and six months appeared to be similar in people with and without cancer. However, we had several concerns regarding the data reported for the subgroup of participants with active cancer due to inconsistencies in the trial report, which prevented us from analysing additional data regarding the primary harm outcome. </p> </section> </section> </section> <section id="CD011782-sec-0143"> <h3 class="title" id="CD011782-sec-0143">Overall completeness and applicability of evidence</h3> <p>Based on the data gathered in this review we have concluded that the pentasaccharide fondaparinux may present with a similar effectiveness/risk balance to what is currently considered to be standard treatment. We found no clear difference in the recurrence of VTE and the frequency of the main harmful effect of the anticoagulant therapy, that is bleeding, in people treated for DVT with fondaparinux plus vitamin K antagonist compared with standard therapy. All‐cause mortality, an important outcome to support the results of the primary efficacy outcome, was also equivalent among participants receiving pentasaccharides and those receiving standard treatment. Finally, the rates of all harmful outcomes also appeared to be comparable between the intervention and the control treatment, though risk of bias and incomplete reporting for this outcome reduces our confidence in this finding. </p> <p>Two of the included studies investigated the effects of fondaparinux, and three evaluated the effects of idraparinux (one of them comparing idraparinux to idrabiotaparinux). Overall, the trials included participants with similar demographic characteristics at baseline. In addition, we believe that the evidence gathered from the primary studies can be considered at a reasonable level of external validity. Most of the participants were between 57 and 62 years old, which is the expected population presenting with higher risk of DVT and the most common population expected to seek treatment for DVT. </p> <p>We found idraparinux to be as efficacious as idrabiotaparinux, and idraparinux as efficacious as standard therapy. Neverthless, the absolute risk of bleeding was increased in participants receiving higher doses of idraparinux and idrabiotaparinux. The observed similar efficacy of idraparinux when compared to standard treatment appears to have occurred at a cost of an increased risk of harmful effects related to higher doses of idraparinux. Harmful outcomes associated with idraparinux showed a clear dose‐response relationship and a high rate of bleeding. These results reveal that doses of idraparinux of 5.0 mg, 7.5 mg, and 10.0 mg may not be safe despite the demonstrated efficacy in the treatment of DVT. </p> <p>Our results showing the lack of acceptable safety of idraparinux are in agreement with previous observations. In fact, idraparinux and idrabiotaparinux were withdrawn from the market due to a high risk of bleeding after treatment of VTE (<a href="./references#CD011782-bbs2-0047" title="HarenbergJ , VukojevicY , MikusG , JoergI , WeissC . Long elimination half‐life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. Journal of Thrombosis and Haemostasis2008;6(5):890‐2. ">Harenberg 2008</a>; <a href="./references#CD011782-bbs2-0081" title="van Gogh Investigators, BullerHR , CohenAT , DavidsonB , DecoususH , GallusAS , et al. Idraparinux versus standard therapy for venous thromboembolic disease. New England Journal of Medicine2007;357(11):1094‐104. ">van Gogh Investigators 2007</a>). Our results did not identify this safety problem with doses of 2.5 mg of idraparinux and equimolar doses of 3.0 mg of idrabiotaparinux, but this result could have occurred by chance. </p> <p>The incidence of HIT, a dangerous harmful outcome relatively common with standard treatment of DVT, was not reported. This can be regarded as a major limitation in the available data. </p> </section> <section id="CD011782-sec-0144"> <h3 class="title" id="CD011782-sec-0144">Quality of the evidence</h3> <p>See <a href="./full#CD011782-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011782-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD011782-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD011782-tbl-0004">summary of findings Table 4</a> </p> <p>We judged five studies, comprising 6981 participants, as providing overall moderate‐ to very low‐quality evidence. As assessed by the GRADE approach, the quality of the evidence provided by the included randomised controlled trials was downgraded mostly due to risk of performance bias, detection bias related to harmful outcomes, and attrition bias related to efficacy and harmful outcomes. In general, only the main harm outcome, bleeding, was consistently measured and reported by the included trials. Key methodological limitations were missing data, withdrawals, and loss to follow‐up not clearly detailed, and data analysis not consistent with an intention‐to‐treat approach. The quality of the evidence for some outcomes was also downgraded due to the inclusion of relatively few events (imprecision). </p> <p>One comparison was particularly problematic: LMWH and idraparinux versus standard therapy. We judged the study providing data for this analysis as potentially flawed since a relevant number of participants were lost to follow‐up or discontinued treatment prematurely after randomisation (<a href="./references#CD011782-bbs2-0003" title="Persist Investigators. A novel long‐acting synthetic Factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood2002; Vol. 100:Abstract 301. Persist Investigators. A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. Journal of Thrombosis and Haemostasis2004;2(1):47‐53. ReiterM , BucekRA , KocaN , HegerJ , MinarE . Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagulation and Fibrinolysis2003;14(1):61‐5. ">PERSIST Trial</a>), and many participants were excluded based on the suspected occurrence of the efficacy outcome (VTE). The study authors described using an intention‐to‐treat approach in their analysis, though this was carried out considering only participants who received treatment. We also downgraded the evidence for this comparison due to unclear risk of selection bias, high risk of performance and attrition bias related to efficacy outcomes, high risk of detection and attrition bias concerning harmful outcomes, and due to the relatively few participants and few events available. </p> </section> <section id="CD011782-sec-0145"> <h3 class="title" id="CD011782-sec-0145">Potential biases in the review process</h3> <p>We planned and implemented our review methods following Cochrane guidance to avoid biases in the review process (<a href="./references#CD011782-bbs2-0048" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We carried out a comprehensive search strategy of the Cochrane Vascular Specialised Register and the Cochrane Central Register of Controlled Trials (CENTRAL). We applied no language restrictions and considered conference abstracts as well as complete articles, which minimises the risk of missing potentially eligible studies. </p> <p>We used a dual selection and data extraction process, with consensus supported by a third review author. A third review author also independently checked data extraction for agreement. These processes were guided by the eligibility criteria established in our review protocol to avoid any subjectivity (<a href="./references#CD011782-bbs2-0086" title="BrandaoGMS , JunqueiraDR , RolloHA , SobreiraML . Pentasaccharides for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD011782] ">Brandao 2015</a>). </p> <p>We adjusted our analysis plan to consider the more consistent measurement of the effect of the interventions. Reports of zero events could not be considered in the analyses, though we attempted to judge whether reports of zero events could be a result of bias. </p> <p>Consequently, we believe that there have been no obvious biases within the review process. </p> </section> <section id="CD011782-sec-0146"> <h3 class="title" id="CD011782-sec-0146">Agreements and disagreements with other studies or reviews</h3> <p>This is the first systematic review evaluating the efficacy and harms of treatment with pentasaccharides in people with DVT. Our results are important to corroborate international guidelines recommending fondaparinux as a treatment option comparable to LMWH and unfractionated heparin followed by vitamin K antagonists for DVT and acute pulmonary embolism (<a href="./references#CD011782-bbs2-0054" title="KearonC , AklEA , ComerotaAJ , PrandoniP , BounameauxH , GoldhaberSZ , et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):e419S‐94S. ">Kearon 2012</a>). To our knowledge, only one non‐Cochrane review has investigated the effects of the pentasaccharides with longer half‐lives, idraparinux and idrabiotaparinux (<a href="./references#CD011782-bbs2-0074" title="SongY , LiX , PavithraS , LiD . Idraparinux or idrabiotaparinux for long‐term venous thromboembolism treatment: a systematic review and meta‐analysis of randomized controlled trials. PLoS ONE2013;8(11):e78972. ">Song 2013</a>). <a href="./references#CD011782-bbs2-0074" title="SongY , LiX , PavithraS , LiD . Idraparinux or idrabiotaparinux for long‐term venous thromboembolism treatment: a systematic review and meta‐analysis of randomized controlled trials. PLoS ONE2013;8(11):e78972. ">Song 2013</a> included two studies not included in our review: Cassiopea, <a href="./references#CD011782-bbs2-0006" title="BullerHR , GallusAS , PillionG , PrinsMH , RaskobGE , the Cassiopea Investigators. Enoxaparin followed by once‐weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double‐blind, double‐dummy, non‐inferiority trial. Lancet2012;379:123‐9. ">Cassiopea Investigators</a>, and van Gogh‐PE, <a href="./references#CD011782-bbs2-0008" title="A multicentre, randomized, open‐label study comparing the efficacy and safety of once daily (o.d.) Org31540/SR90107A versus adjusted dose intravenous (i.v.) unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism (PE) (MATISSE‐PE). Study No: 63123. GlaxoSmithKline Clinical Trial Register2005. BullerHR , DavidsonBL , DecoususH , GallusA , GentM , PiovellaF , et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. New England Journal of Medicine2003;349(18):1695‐702. DavidsonBL , BullerHR , DecoususH , GallusA , GentM , PiovellaF , et al. Outcomes in obese patients of pulmonary embolism (PE) and deep vein thrombosis (DVT) treatment with fondaparinux or (LMW) heparins: the Matisse trials. Journal of Thrombosis and Haemostasis2005;3(Suppl S1):P0424. DavidsonBL , the Matisse Steering Committee and Investigators. Fondaparinux, a pentasaccharide vs unfractionated heparin (UH) or low molecular weight heparin (LMWH) for pulmonary embolism (PE) or deep vein thrombosis (DVT): the Matisse trials [abstract]. American Thoracic Society 99th International Conference. 2003:A119. Matisse Investigators. Fondaparinux (Arixtra) in comparison to (low molecular weight) heparin for the initial treatment of symptomatic deep venous thrombosis or pulmonary embolism ‐ the Matisse clinical outcome studies. Blood2002; Vol. 100:Abstract 302. PiovelaF . Initial outpatient treatment of pulmonary embolism with fondaparinux (Arixtra): the Matisse‐Pe trial. Hematology Journal2004;Suppl 2:53. The Matisse Investigators. The MATISSE‐PE trial, a multicenter, randomized, open study comparing once‐daily fondaparinux (Arixtra®) with adjusted‐dose intravenous unfractionated heparin (UFH) in the initial treatment of acute symptomatic pulmonary embolism. Journal of Thrombosis and Haemostasis2003; Vol. 1, issue Suppl 1:Abstract number OC331. ">MATISSE‐PE</a>. We did not include these studies because they investigated people treated for DVT and pulmonary embolism, and did not report data separately to permit the extraction of data only for participants treated for DVT. <a href="./references#CD011782-bbs2-0074" title="SongY , LiX , PavithraS , LiD . Idraparinux or idrabiotaparinux for long‐term venous thromboembolism treatment: a systematic review and meta‐analysis of randomized controlled trials. PLoS ONE2013;8(11):e78972. ">Song 2013</a> did not find convincing evidence that idraparinux and idrabiotaparinux had a profile of efficacy and harm outcome comparable to standard treatment. This is in agreement with our results. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011782-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011782-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011782-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011782-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.1 Recurrent VTE at 3 months' follow‐up." data-id="CD011782-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.1 Recurrent VTE at 3 months' follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.2 Bleeding [initial treatment]." data-id="CD011782-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.2 Bleeding [initial treatment]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.3 Major bleeding [initial treatment]." data-id="CD011782-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.3 Major bleeding [initial treatment]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.12 Recurrent VTE at 3 months' follow‐up [body weight]." data-id="CD011782-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Fondaparinux plus vitamin K antagonist versus standard therapy, outcome: 1.12 Recurrent VTE at 3 months' follow‐up [body weight]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 1 Recurrent VTE [3‐months follow‐up]." data-id="CD011782-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 1 Recurrent VTE [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 2 Bleeding [initial treatment]." data-id="CD011782-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 2 Bleeding [initial treatment]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 3 Major bleeding [initial treatment]." data-id="CD011782-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 3 Major bleeding [initial treatment]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 4 Clinically relevant bleeding [initial treatment]." data-id="CD011782-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 4 Clinically relevant bleeding [initial treatment]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 5 Bleeding [3‐months follow‐up]." data-id="CD011782-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 5 Bleeding [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 6 Major bleeding [3‐months follow‐up]." data-id="CD011782-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 6 Major bleeding [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 7 Clinically relevant bleeding [3‐months follow‐up]." data-id="CD011782-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 7 Clinically relevant bleeding [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 8 All‐cause mortality [3‐months follow‐up]." data-id="CD011782-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 8 All‐cause mortality [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 9 Recurrent DVT [3‐months follow‐up]." data-id="CD011782-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 9 Recurrent DVT [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 10 Pulmonary embolism [3‐months follow‐up]." data-id="CD011782-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 10 Pulmonary embolism [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 11 Harmful effects leading to premature discontinuation." data-id="CD011782-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 11 Harmful effects leading to premature discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 12 All harmful effects [3‐months follow‐up]." data-id="CD011782-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 12 All harmful effects [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 13 Serious adverse effects [3‐months follow‐up]." data-id="CD011782-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 13 Serious adverse effects [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-14.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 14 Recurrent VTE [3‐months follow‐up] [body weight]." data-id="CD011782-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 14 Recurrent VTE [3‐months follow‐up] [body weight]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 15 Recurrent VTE [3‐months follow‐up] [outpatient treatment]." data-id="CD011782-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 15 Recurrent VTE [3‐months follow‐up] [outpatient treatment]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 16 Major bleeding [3‐months follow‐up] [outpatient treatment]." data-id="CD011782-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 16 Major bleeding [3‐months follow‐up] [outpatient treatment]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 17 Recurrent VTE [3‐months follow‐up] [participants with active cancer]." data-id="CD011782-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 17 Recurrent VTE [3‐months follow‐up] [participants with active cancer]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 18 Bleeding [3‐months follow‐up] [participants with active cancer]." data-id="CD011782-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 18 Bleeding [3‐months follow‐up] [participants with active cancer]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 19 Major bleeding [3‐months follow‐up] [participants with active cancer]." data-id="CD011782-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 19 Major bleeding [3‐months follow‐up] [participants with active cancer]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 20 Clinically relevant bleeding [3‐months follow‐up] [participants with active cancer]." data-id="CD011782-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Fondaparinux plus vitamin K antagonist versus standard therapy, Outcome 20 Clinically relevant bleeding [3‐months follow‐up] [participants with active cancer]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 1 Recurrent VTE [6‐months follow‐up]." data-id="CD011782-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 1 Recurrent VTE [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 2 Recurrent VTE [9‐months follow‐up]." data-id="CD011782-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 2 Recurrent VTE [9‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 3 Bleeding [6‐months follow‐up]." data-id="CD011782-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 3 Bleeding [6‐months follow‐up].</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 4 Major bleeding [6‐months follow‐up]." data-id="CD011782-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 4 Major bleeding [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 5 Clinically relevant bleeding [6‐months follow‐up]." data-id="CD011782-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 5 Clinically relevant bleeding [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 6 Bleeding [9‐months follow‐up]." data-id="CD011782-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 6 Bleeding [9‐months follow‐up].</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 7 Major bleeding [9‐months follow‐up]." data-id="CD011782-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 7 Major bleeding [9‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 8 Clinically relevant bleeding [9‐months follow‐up]." data-id="CD011782-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 8 Clinically relevant bleeding [9‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 9 All‐cause mortality [6‐months follow‐up]." data-id="CD011782-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 9 All‐cause mortality [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 10 All‐cause mortality [9‐months follow‐up]." data-id="CD011782-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 10 All‐cause mortality [9‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 11 Recurrent DVT [6‐months follow‐up]." data-id="CD011782-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 11 Recurrent DVT [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 12 Pulmonary embolism [6‐months follow‐up]." data-id="CD011782-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 12 Pulmonary embolism [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 13 Harmful effects leading to premature discontinuation." data-id="CD011782-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 13 Harmful effects leading to premature discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 14 All harmful effects." data-id="CD011782-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Idrabiotaparinux versus idraparinux, Outcome 14 All harmful effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 1 Recurrent VTE [idraparinux 10 mg]." data-id="CD011782-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 1 Recurrent VTE [idraparinux 10 mg]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 2 Bleeding [idraparinux 2.5 mg]." data-id="CD011782-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 2 Bleeding [idraparinux 2.5 mg]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 3 Bleeding [idraparinux 5.0 mg]." data-id="CD011782-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 3 Bleeding [idraparinux 5.0 mg]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 4 Bleeding [idraparinux 7.5 mg]." data-id="CD011782-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 4 Bleeding [idraparinux 7.5 mg]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 5 Bleeding [idraparinux 10 mg]." data-id="CD011782-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 5 Bleeding [idraparinux 10 mg]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 6 Bleeding [all doses]." data-id="CD011782-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 6 Bleeding [all doses]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 7 Major bleeding [all doses]." data-id="CD011782-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 7 Major bleeding [all doses]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 8 Harmful effects leading to premature discontinuation." data-id="CD011782-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 LMWH and idraparinux versus standard therapy, Outcome 8 Harmful effects leading to premature discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 1 Recurrent VTE [3‐months follow‐up]." data-id="CD011782-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 1 Recurrent VTE [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 2 Recurrent VTE [6‐months follow‐up]." data-id="CD011782-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 2 Recurrent VTE [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 3 Bleeding [3‐months follow‐up]." data-id="CD011782-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 3 Bleeding [3‐months follow‐up].</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 4 Major bleeding [3‐months follow‐up]." data-id="CD011782-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 4 Major bleeding [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 5 Clinically relevant bleeding [3‐months follow‐up]." data-id="CD011782-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 5 Clinically relevant bleeding [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 6 Bleeding [6‐months follow‐up]." data-id="CD011782-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 6 Bleeding [6‐months follow‐up].</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 7 Major bleeding [6‐months follow‐up]." data-id="CD011782-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 7 Major bleeding [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 8 Clinically relevant bleeding [6‐months follow‐up]." data-id="CD011782-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 8 Clinically relevant bleeding [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 9 All‐cause mortality [3‐months follow‐up]." data-id="CD011782-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 9 All‐cause mortality [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 10 All‐cause mortality [6‐months follow‐up]." data-id="CD011782-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 10 All‐cause mortality [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 11 Recurrent DVT [3‐months follow‐up]." data-id="CD011782-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 11 Recurrent DVT [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 12 Recurrent DVT [6‐months follow‐up]." data-id="CD011782-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 12 Recurrent DVT [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 13 Recurrent PE [3‐months follow‐up]." data-id="CD011782-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 13 Recurrent PE [3‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 14 Recurrent PE [6‐months follow‐up]." data-id="CD011782-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 14 Recurrent PE [6‐months follow‐up]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 15 Harmful effects leading to premature discontinuation." data-id="CD011782-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 15 Harmful effects leading to premature discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 16 All harmful effects." data-id="CD011782-fig-0065" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 16 All harmful effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 17 Recurrent VTE [3‐months follow‐up] [participants with active cancer]." data-id="CD011782-fig-0066" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 17 Recurrent VTE [3‐months follow‐up] [participants with active cancer]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011782-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/urn:x-wiley:14651858:media:CD011782:CD011782-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_t/tCD011782-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Idraparinux versus standard therapy, Outcome 18 Recurrent VTE [6‐months follow‐up] [participants with active cancer]." data-id="CD011782-fig-0067" src="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Idraparinux versus standard therapy, Outcome 18 Recurrent VTE [6‐months follow‐up] [participants with active cancer]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/media/CDSR/CD011782/image_n/nCD011782-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011782-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fondaparinux plus vitamin K antagonist compared to standard therapy for the treatment of deep vein thrombosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fondaparinux plus vitamin K antagonist compared to standard therapy for the treatment of deep vein thrombosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people &gt; 18 years of age with a diagnosed deep vein thrombosis<br/> <b>Setting:</b> hospitalised and non‐hospitalised patients<br/> <b>Intervention:</b> fondaparinux plus vitamin K antagonist<br/> <b>Comparison:</b> standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with fondaparinux plus vitamin K antagonist</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/> (0.43 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2658<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (18 to 61) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment<br/> Follow‐up: 5 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.15<br/> (0.39 to 3.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2645<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In contrast with other harm outcomes, bleeding was not subjected to detection bias.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (4 to 37) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.64 to 1.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2645<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In contrast with other harm outcomes, bleeding was not subjected to detection bias.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/> (15 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/> (0.45 to 1.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2645<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (15 to 65) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin‐induced thrombocytopenia ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>7 participants in each treatment group of the MATISSE‐DVT trial developed thrombocytopenia. This represents a frequency of thrombocytopenia approximately equal to 0.64% in both groups. None of the thrombocytopenic participants were reported as having developed heparin‐induced thrombocytopenia antibodies, and none of the cases were associated with thromboembolism events. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The MATISSE‐DVT trial reported no definition of thrombocytopenia and a non‐standard definition of heparin‐induced thrombocytopenia. It was stated that laboratory tests were used in the diagnosis of heparin‐induced thrombocytopenia, but the report related to these tests was incomplete. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All harmful effects<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.84<br/> (0.76 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2192<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000<br/> (340 to 416) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*We calculated the assumed risk of the standard therapy group from the average risk in the standard therapy group (i.e. the number of participants with events divided by total number of participants of the standard therapy group included in the meta‐analysis). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect,<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to unclear risk of bias in multiple criteria (selection bias, performance bias, and attrition bias related to efficacy outcomes) and high risk of attrition bias related to efficacy outcomes in one study.<br/> <sup>2</sup>Downgraded for high risk of detection bias related to harm outcomes.<br/> <sup>3</sup>Downgraded twice for high risk of detection and attrition bias related to harm outcomes.<br/> <sup>4</sup>Downgraded for imprecision caused by single study and small number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fondaparinux plus vitamin K antagonist compared to standard therapy for the treatment of deep vein thrombosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011782-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Idrabiotaparinux compared to idraparinux for the treatment of deep vein thrombosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Idrabiotaparinux compared to idraparinux for the treatment of deep vein thrombosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people &gt; 18 years of age with a diagnosed deep vein thrombosis<br/> <b>Setting:</b> hospitalised and non‐hospitalised patients<br/> <b>Intervention:</b> idrabiotaparinux<br/> <b>Comparison:</b> idraparinux </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with idraparinux</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with idrabiotaparinux</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.72<br/> (0.31 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>757<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (10 to 55) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding during the initial treatment ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding during the initial treatment period was not reported in the single included study in this comparison. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21<br/> (0.06 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>755<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>While bleeding was considered a main harm outcome, it was diagnosed by a committee unaware of treatment assignment and was therefore judged as not influenced by detection bias. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/> (2 to 27) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.48<br/> (0.18 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>757<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (6 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Heparin‐induced thrombocytopenia ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition for or data on thrombocytopenia or heparin‐induced thrombocytopenia</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All harmful effects<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/> (0.83 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>757<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>685 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>630 per 1000<br/> (568 to 698) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*We calculated the assumed risk of the idraparinux group from the average risk in the idraparinux group (i.e. the number of participants with events divided by total number of participants of the idraparinux group included in the meta‐analysis). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to high risk of attrition bias related to efficacy outcome.<br/> <sup>2</sup>Downgraded due to imprecision caused by single study and small number of events.<br/> <sup>3</sup>Downgraded due to high risk of attrition bias related to harm outcome.<br/> <sup>4</sup>Downgraded twice due to high risk of detection and attrition bias related to harm outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Idrabiotaparinux compared to idraparinux for the treatment of deep vein thrombosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011782-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Low molecular weight heparin and idraparinux compared to standard therapy for the treatment of deep vein thrombosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low molecular weight heparin (LMWH) and idraparinux compared to standard therapy for the treatment of deep vein thrombosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people &gt; 18 years of age with a diagnosed deep vein thrombosis<br/> <b>Setting:</b> hospitalised and non‐hospitalised patients<br/> <b>Intervention:</b> LMWH and idraparinux<br/> <b>Comparison:</b> standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with LMWH and idraparinux</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/> assessed with: idraparinux 10 mg<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.51<br/> (0.26 to 8.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>263<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (4 to 135) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment<br/> Follow‐up: 5 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment period was not reported in the single included study in this comparison. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/> assessed with: all doses<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.76<br/> (0.50 to 28.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>659<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/> (4 to 214) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>A total of 7 cases (of 527 participants) were reported in the group receiving idraparinux after LMWH and zero deaths (of 132 participants) in the group receiving standard therapy. Zero events in the group receiving standard therapy prevented us from conducting a pooled analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study providing data for this comparison was deemed at high risk of bias for incomplete outcome data. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heparin‐induced thrombocytopenia<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The published report stated that no events of heparin‐induced thrombocytopenia were observed, although without providing any details on how it was assessed and diagnosed. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All harmful effects<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Data on harmful effects were not provided for any of the treatment groups.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The published report stated that "adverse effects were distributed similarly between the groups", but reported an increase in the alanine aminotransferase levels in 15% of participants during the initial LMWH phase. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*We calculated the assumed risk of the standard group from the average risk in the standard therapy group (i.e. the number of participants with events divided by total number of participants of the standard therapy group included in the meta‐analysis). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded twice due to unclear risk of selection bias and high risk of performance and attrition bias related to efficacy outcomes.<br/> <sup>2</sup>Downgraded due to imprecision caused by single study and small number of participants and events.<br/> <sup>3</sup>Downgraded twice due to high risk of detection and attrition bias related to harm outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Low molecular weight heparin and idraparinux compared to standard therapy for the treatment of deep vein thrombosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011782-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Idraparinux compared to standard therapy for the treatment of deep vein thrombosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Idraparinux compared to standard therapy for the treatment of deep vein thrombosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people &gt; 18 years of age with a diagnosed deep vein thrombosis<br/> <b>Setting:</b> hospitalised and non‐hospitalised patients<br/> <b>Intervention:</b> idraparinux<br/> <b>Comparison:</b> standard therapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard therapy</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with idraparinux</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Recurrent venous thromboembolism<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.98<br/> (0.64 to 1.48) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2904<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (19 to 44) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment<br/> Follow‐up: 5 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding during the initial treatment period was not reported in the single included study in this comparison. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Major bleeding<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.71<br/> (0.34 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2904<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/> (4 to 17) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.14<br/> (0.69 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2904<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000<br/> (14 to 37) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Heparin‐induced thrombocytopenia<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No definition for or data on thrombocytopenia and heparin‐induced thrombocytopenia were reported. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All harmful effects<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.03<br/> (1.00 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2904<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>1, 2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>874 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>900 per 1000<br/> (874 to 926) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*We calculated the assumed risk of the standard therapy group from the average risk in the standard therapy group (i.e. the number of participants with events divided by total number of participants of the standard therapy group included in the meta‐analysis). <b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to high risk of performance bias.<br/> <sup>2</sup>Downgraded due to imprecision caused by single study and small number of events.<br/> <sup>3</sup>Downgraded due to high risk of attrition bias related to harm outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Idraparinux compared to standard therapy for the treatment of deep vein thrombosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011782-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies: Methods</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Countries</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Funding sources</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQUINOX</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006/2007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Israel, Italy, Mexico, the Netherlands, New Zealand, Poland, Russia, South Africa, Spain, USA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MATISSE‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2000/2001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Russia, South Africa, Spain, Sweden, Switzerland, UK, USA </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi and NV Organon</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PERSIST Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999/2001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Austria, Denmark, Italy, the Netherlands, Poland, Spain, Sweden, UK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi and NV Organon</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Rembrandt Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997/1998</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia, Belgium, Canada, France, Italy, New Zealand, Switzerland</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi and NV Organon</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Van Gogh Trial‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2003/2004</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia, Canada, France, Italy, the Netherlands, UK, USA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sanofi</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Characteristics of included studies: Methods</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011782-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies: Participants</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of randomised participants</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Age (mean)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exclusion criteria</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQUINOX</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0018"> <li> <p>symptomatic pulmonary embolism;</p> </li> <li> <p>active bleeding or high risk of bleeding;</p> </li> <li> <p>creatinine clearance &lt; 30 mL per min;</p> </li> <li> <p>severe hepatic disease;</p> </li> <li> <p>bacterial endocarditis;</p> </li> <li> <p>uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg); </p> </li> <li> <p>known allergy to idraparinux, idrabiotaparinux, or egg proteins;</p> </li> <li> <p>therapeutic doses of LMWH, unfractionated heparin, or fondaparinux given for more than 36 hours before randomisation; </p> </li> <li> <p>initiation of vitamin K antagonist treatment or treatment with thrombolysis, thrombectomy, or a vena cava filter for the current episode of deep vein thrombosis; </p> </li> <li> <p>another indication for prolonged anticoagulant therapy;</p> </li> <li> <p>life expectancy of &lt; 6 months;</p> </li> <li> <p>participation in another pharmacotherapeutic study within the prior 30 days;</p> </li> <li> <p>pregnant women, breastfeeding or premenopausal and not using effective contraceptive measures. </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MATISSE‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2205</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0019"> <li> <p>symptomatic pulmonary embolism;</p> </li> <li> <p>received therapeutic doses of LMWH or oral anticoagulants for more than 24 hours;</p> </li> <li> <p>required thrombolysis, thrombectomy, or a vena cava filter;</p> </li> <li> <p>anticoagulant therapy contraindication (e.g. active bleeding, thrombocytopenia (platelet count 100,000 x 10<sup>9</sup>/L)); </p> </li> <li> <p>elevated serum creatinine levels above 177 µmol/L (2 mg/dL);</p> </li> <li> <p>uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg); </p> </li> <li> <p>pregnancy;</p> </li> <li> <p>had a life expectancy &lt; 3 months.</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PERSIST Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>659</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0020"> <li> <p>symptoms for more than 14 days;</p> </li> <li> <p>symptomatic pulmonary embolism;</p> </li> <li> <p>documented DVT within the last 2 years;</p> </li> <li> <p>surgery within the past 10 days;</p> </li> <li> <p>more than 32 hours of therapeutic anticoagulant treatment;</p> </li> <li> <p>contraindications for anticoagulants;</p> </li> <li> <p>life expectancy &lt; 3 months;</p> </li> <li> <p>pregnancy;</p> </li> <li> <p>serum creatinine &gt; 200 µmol/L;</p> </li> <li> <p>platelet count &lt; 100 × 10<sup>9</sup>/L. </p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Rembrandt Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>456</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0021"> <li> <p>symptomatic pulmonary embolism;</p> </li> <li> <p>previously documented thrombosis in the same leg, unless complete ultrasound normalisation had been documented; </p> </li> <li> <p>known bleeding tendency;</p> </li> <li> <p>surgery within the previous 5 days;</p> </li> <li> <p>body weight of &lt; 50 kg or &gt; 100 kg;</p> </li> <li> <p>any contraindication for anticoagulant treatment;</p> </li> <li> <p>treatment with therapeutic dosages of anticoagulants for &gt; 24 hours before randomisation;</p> </li> <li> <p>pregnant women, breastfeeding or premenopausal and not using effective contraceptive measures; </p> </li> <li> <p>drug‐addictive disorder or alcoholism;</p> </li> <li> <p>known renal insufficiency;</p> </li> <li> <p>life expectancy of &lt; 6 months;</p> </li> <li> <p>participation in another clinical drug study within the previous 90 days.</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Van Gogh Trial‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2904</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who had presented with or documented:</p> <p> <ul id="CD011782-list-0022"> <li> <p>treatment with a therapeutic dose of LMWH or unfractionated heparin for more than 36 hours before randomisation; </p> </li> <li> <p>treatment with thrombolysis, embolectomy, or a vena cava filter required for the current episode; </p> </li> <li> <p>another indication for a vitamin K antagonist;</p> </li> <li> <p>pregnancy or breastfeeding;</p> </li> <li> <p>creatinine clearance of less than 10 mL per minute;</p> </li> <li> <p>uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg); </p> </li> <li> <p>life expectancy of &lt; 3 months.</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>DVT: deep vein thrombosis<br/> LMWH: low molecular weight heparin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Characteristics of included studies: Participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011782-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies: Outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary efficacy outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary harm outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time points measured of outcomes</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQUINOX</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Idrabiotaparinux: 3.0 mg once a week for 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Idraparinux: 2.5 mg once a week for 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 and 9 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MATISSE‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) fondaparinux: 5.0 mg (weight &lt; 50 kg) or 7.5 mg (50 kg &gt; weight &lt; 100 kg) or 10 mg (weight &gt; 100 kg) once daily for 5 days; </p> <p>(2) vitamin K antagonist started within 72 hours and continued for 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard therapy:</p> <p>(1) enoxaparin: 1 mg/kg twice daily for 5 days;</p> <p>(2) vitamin K antagonist started within 72 hours and continued for 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PERSIST Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) 5 to 7 days of LMWH (enoxaparin, 1 mg/kg);</p> <p>(2) idraparinux: 2.5 mg, 5 mg, 7.5 mg, or 10 mg once a week without weight adjustment continued for 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard therapy:</p> <p>(1) 5 to 7 days of enoxaparin (1 mg/kg);</p> <p>(2) warfarin target to an INR rate between 2.0 to 3.0 continued for 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Rembrandt Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(1) fondaparinux: 5.0 mg, 7.5 mg, or 10 mg once daily without weight adjustment for ± 5 days; </p> <p>(2) vitamin K antagonist started on day 1 or 2 and continued for ± 90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard therapy:</p> <p>(1) dalteparin: 100 IU/kg twice daily for ± 5 days;</p> <p>(2) vitamin K antagonist started on day 1 or 2 and continued for ± 90 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>The Van Gogh Trial‐DVT</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Idraparinux: 2.5 mg once a week for 3 or 6 months, as assessed by the treating physician</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Standard therapy:</p> <p>(1) tinzaparin, enoxaparin, or intravenous heparin: dose adjusted for the activated partial thromboplastin time (ratio 1.5 to 2.5); </p> <p>(2) warfarin or acenocoumarol started within 24 hours and target to INR 2.0 to 3.0 for 3 or 6 months, as assessed by the treating physician </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic recurrent venous thromboembolism</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant bleeding and all‐cause mortality</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 or 6 months</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>INR: international normalised ratio<br/> LMWH: low molecular weight heparin </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Characteristics of included studies: Outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011782-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Relative risks of the 10 most frequent harmful effects during the initial treatment with fondaparinux versus standard treatment (LMWH, enoxaparin, for 5 days)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harmful effect, n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fondaparinux (n = 1091)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Enoxaparin (n = 1101)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (2.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (2.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.56 to 1.58)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constipation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (1.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (2.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.38 to 1.14)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diarrhoea</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (1.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (2.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69 (0.36 to 1.32)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Vomiting</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (1.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94 (0.44 to 1.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bruise</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (0.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38 (0.18 to 0.81)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Haematoma</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (1.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77 (0.38 to 1.58)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (2.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (2.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 (0.47 to 1.32)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hepatic enzymes increased</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (0.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (4.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08 (0.03 to 0.21)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SGPT increased</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (0.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 (4.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04 (0.01 to 0.18)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SGOT increased</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (2.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03 (0.00 to 0.24)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Headache</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (3.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (3.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95 (0.61 to 1.50)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coughing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (1.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (0.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.02 (0.82 to 4.98)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pneumonia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (0.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.62 (0.94 to 7.33)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Insomnia</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (2.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19 (1.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 (0.74 to 2.40)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Urinary tract infection</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (2.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (1.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 (0.47 to 1.37)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval<br/> LMWH: low molecular weight heparin<br/> SGOT: serum glutamic oxaloacetic transaminase<br/> SGPT: serum glutamic pyruvic transaminase </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Relative risks of the 10 most frequent harmful effects during the initial treatment with fondaparinux versus standard treatment (LMWH, enoxaparin, for 5 days)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011782-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Relative risks of harmful effects induced by idrabiotaparinux versus idraparinux</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harmful effects, n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idrabiotaparinux</b> </p> <p><b>(n = 385)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idraparinux</b> </p> <p><b>(n = 370)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223 (57.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227 (61.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.84 to 1.06)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Infections and infestations</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (17.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 (22.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.59 to 1.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nasopharyngitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (3.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.66 to 4.14)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urinary tract infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.36 to 2.53)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bronchitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.26 to 1.75)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (1.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.25 to 2.06)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Musculoskeletal and connective tissue disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 (12.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (11.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.73 to 1.57)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain in extremity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (3.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35 (0.61 to 2.99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arthralgia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (2.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77 (0.31 to 1.93)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (10.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48 (13.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.54 to 1.19)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (2.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08 (0.42 to 2.77)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vascular disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (10.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (9.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.71 to 1.69)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haematoma</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (3.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (5.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.37 to 1.39)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (2.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.54 to 1.19)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Injury, poisoning, and procedural complications</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (9.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (11.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.55 to 1.25)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Accidental overdose*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (5.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (3.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.55 (0.79 to 3.05)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fall</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (1.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (3.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40 (0.14 to 1.13)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nervous system disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (9.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (8.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.14 (0.73 to 1.79)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (4.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 (4.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.22 (0.63 to 2.36)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>General disorders and administration site conditions</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (8.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (11.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.51 to 1.19)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oedema peripheral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (3.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52 (0.21 to 1.28)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Respiratory, thoracic, and mediastinal disorders</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (8.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (7.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.66 to 1.72)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Epistaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (3.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (1.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.65 (0.66 to 4.14)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Overdose is defined as two or more injections of the study drug in five days or fewer.</p> <p>CI: confidence interval</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Relative risks of harmful effects induced by idrabiotaparinux versus idraparinux</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011782-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Relative risks of harmful effects induced by idraparinux versus standard therapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects, n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Idraparinux</b> </p> <p><b>(n = 1452)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Standard therapy (n = 1452)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 (6.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 (6.27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 (0.81 to 1.41)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (0.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (1.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33 (0.13 to 0.84)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash, dermatitis, or urticaria</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (4.27)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (3.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.35 (0.93 to 1.96)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 (18.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>295 (20.31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.76 to 1.03)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other event</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>778 (53.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>754 (51.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.96 to 1.11)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Relative risks of harmful effects induced by idraparinux versus standard therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/full#CD011782-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011782-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fondaparinux plus vitamin K antagonist versus standard therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrent VTE [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.43, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding [initial treatment] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.56, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Major bleeding [initial treatment] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.39, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinically relevant bleeding [initial treatment] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Bleeding [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.50, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Major bleeding [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.64, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinically relevant bleeding [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.68, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.45, 1.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Recurrent DVT [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.36, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Pulmonary embolism [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.23, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Harmful effects leading to premature discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.40, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 All harmful effects [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serious adverse effects [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2192</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.84, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Recurrent VTE [3‐months follow‐up] [body weight] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Recurrent VTE [body weight &lt; 50 kg]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.03, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Recurrent VTE [body weight 50‐100 kg]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.63, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Recurrent VTE [body weight &gt; 100 kg]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.37, 6.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Recurrent VTE [3‐months follow‐up] [outpatient treatment] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Recurrent VTE [inpatient treatment]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.75, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Recurrent VTE [outpatient treatment]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.20, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Major bleeding [3‐months follow‐up] [outpatient treatment] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Major bleeding [inpatient treatment]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.26, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Major bleeding [outpatient treatment]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.34 [1.23, 15.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Recurrent VTE [3‐months follow‐up] [participants with active cancer] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Recurrent VTE [participants with no cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.44, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Recurrent VTE [participants with active cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [0.95, 5.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Bleeding [3‐months follow‐up] [participants with active cancer] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Major bleeding [participants with no cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.68, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Major bleeding [participants with active cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.62, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Major bleeding [3‐months follow‐up] [participants with active cancer] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Major bleeding [participants with no cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.57, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Major bleeding [participants with active cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.40, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Clinically relevant bleeding [3‐months follow‐up] [participants with active cancer] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Clinically relevant bleeding [participants with no active cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.82 [2.03, 7.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Clinically relevant bleeding [participants with active cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.54, 2.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fondaparinux plus vitamin K antagonist versus standard therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011782-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Idrabiotaparinux versus idraparinux</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrent VTE [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.31, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrent VTE [9‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.28, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Bleeding [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.33, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major bleeding [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.06, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinically relevant bleeding [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.41, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Bleeding [9‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Major bleeding [9‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.11, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinically relevant bleeding [9‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.46, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.18, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 All‐cause mortality [9‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.28, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Recurrent DVT [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.14, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Pulmonary embolism [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.28, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Harmful effects leading to premature discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.41, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 All harmful effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Idrabiotaparinux versus idraparinux</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011782-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">LMWH and idraparinux versus standard therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrent VTE [idraparinux 10 mg] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.26, 8.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bleeding [idraparinux 2.5 mg] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.08, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Bleeding [idraparinux 5.0 mg] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.69, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Bleeding [idraparinux 7.5 mg] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.82, 3.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Bleeding [idraparinux 10 mg] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.91, 3.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Bleeding [all doses] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.70, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Major bleeding [all doses] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.76 [0.50, 28.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Harmful effects leading to premature discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.89, 3.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">LMWH and idraparinux versus standard therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011782-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Idraparinux versus standard therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Recurrent VTE [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.64, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Recurrent VTE [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.66, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Bleeding [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.48, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Major bleeding [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.34, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinically relevant bleeding [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Bleeding [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.78, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Major bleeding [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.66, 2.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinically relevant bleeding [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.72, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.69, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 All‐cause mortality [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.85, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Recurrent DVT [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.49, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Recurrent DVT [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.53, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Recurrent PE [3‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.38, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Recurrent PE [6‐months follow‐up] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.57, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Harmful effects leading to premature discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.17, 2.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 All harmful effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [1.00, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Recurrent VTE [3‐months follow‐up] [participants with active cancer] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Recurrent VTE [3‐months follow‐up] [participants with no cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.75, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Recurrent VTE [3‐months follow‐up] [participants with active cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.15, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Recurrent VTE [6‐months follow‐up] [participants with active cancer] <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Recurrent VTE [6‐months follow‐up] [participants with no cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.78, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Recurrent VTE [6‐months follow‐up] [participants with active cancer]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.14, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Idraparinux versus standard therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011782.pub2/references#CD011782-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011782.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011782-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011782-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011782-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="pl#CD011782-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011782-note-0015">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011782\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011782\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011782\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011782\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011782\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ytRBD0EW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011782.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011782.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011782.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011782.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011782.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729525730"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011782.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729525734"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011782.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edf090f52bd65',t:'MTc0MDcyOTUyNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 